WO2021151212A1

WO2021151212A1 - System and method for quantifying, formulating and enhancing user experience profile of cannabis

Info

Publication number: WO2021151212A1
Application number: PCT/CA2021/050107
Authority: WO
Inventors: Martha Rosalie BAJEC; Thong Trinh
Original assignee: Hexo Operations Inc.
Priority date: 2020-01-31
Filing date: 2021-01-29
Publication date: 2021-08-05

Abstract

The present disclosure relates to methods and systems of quantifying a user experience profile associated with a cannabis strain based on the physiological, psychoactive and/or organoleptic effects attributable to the cannabinoids and terpenes. The disclosure also relates to methods of using the quantified user experience profile to recreate a more consistent user experience to the known user experience profile associated with the cannabis strain, or create an enhanced user experience profile that selectively focuses on those cannabinoids and/or terpenes that provide the desired effects. Also disclosed are cannabinoid products comprising a modified terpene profile, a modified cannabinoid profile or both, useful to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification.

Description

SYSTEM AND METHOD FOR QUANTIFYING, FORMULATING AND ENHANCING USER EXPERIENCE PROFILE OF CANNABIS

TECHNICAL FIELD

[0001] The present disclosure relates to a system and method for quantifying, formulating and/or enhancing user experience profde associated with a cannabis strain.

BACKGROUND

[0002] It is well-known that cannabinoids and terpenes work together to provide the full physiological, psychological and/or sensorial effects collectively described as the unique “user experience profile” associated with a particular cannabis strain. The types and levels of these cannabinoids and terpenes vary between the different cannabis strains. The typical breakdown for some popular cannabis strains (e.g., Pineapple Express, Granddaddy Purple, Purple Haze, etc.) are summarized in Table 1, which shows the major cannabinoid and terpene profiles associated with certain aroma/flavors.

Table 1 - Cannabis Strains

Source: https://productiongrower.com/blogs/marijuana-products/strains.

[0003] As evidence from Table 1, Tetrahydrocannabinol (THC) and Cannabidiol (CBD) are the two most prominent cannabinoids responsible for the majority of the physiological and psychoactive effects associated with most cannabis strains. However, both of these compounds are near-flavorless and -odorless when isolated. The flavors and aroma that define the user experience profile for any cannabis strains when consumed (e.g., inhaled, ingest) are the results of the terpene profile. Different cannabis strains can have dramatically different cannabinoid profile and terpene profile that generate the known user experience profile associated with that particular cannabis strain. The challenge for consumers is that even though two varieties of cannabis strains are sold under the same name, it oftentimes does not mean that they indeed share the same cannabinoid and terpene profile, or provide the same user experience profile. Therefore, what is needed is a practical method to more directly and accurately quantify the unique user experience profile associated with a particular cannabis strain in order to enable the production of comparable high- quality products safeguarding quality and consistency.

[0004] Furthermore, the cannabinoid and terpene profile in combination are thought to be responsible for the “entourage effect”. The traditional understanding is that the “entourage effect” is attributable to the more prevalent cannabinoids (e.g., THC, CBD) and terpenes (e.g., caryophyllene, myrcene, limonene, etc.), while the other minor cannabinoids and terpenes are of relative insignificance.

[0005] Typically, the most prevalent terpenes are the ones present at the highest concentration in the blend. The “entourage effect” dictates that these prevalent terpenes are responsible for the characteristic aromas, flavors and/or effects associated with the cannabis strain. As a result, previous attempts to recreate the unique user experience profile for any particular cannabis strain have focused on selecting these major terpenes, which may not be truly representative of the full spectrum of the user experience.

[0006] In fact, there are thousands of varieties of cannabis having different chemotypes (i.e., chemical phenotypes) which demonstrate effects beyond the mere major cannabinoids and terpenes. According to recent reports, small amounts of highly odorous compounds present in headspace of cannabis are more likely responsible for contributing to the overall odor profile of the cannabis (Rice, S., et al., Forensic Science International 257, 257-270 (2015)). Rice also emphasized that “previous reports of the most abundant compounds in headspace can mislead researchers when dealing with whole odor of these” cannabis and “(t)here were no apparent correlations between concentrations and odor activity values (OAVs)” (supra, see Abstract). Therefore, highly impactful odor compounds that may be found in smaller concentration have been easily overlooked or ignored.

[0007] So it would seem that the variety of cannabis strains may indeed be better characterized as having an “ensemble effect”, rather than an “entourage effect”. For example, one can think of the “ensemble effect” as an orchestra whereby each individual instrument contributes to the overall experience of the musical piece. By analogy, the THC may be considered as the conductor, and CBD as the first-chair violin, but each additional cannabinoid and terpene still contributes to the overall user experience. Therefore, it is desirable that the method used to quantify the unique user experience takes into account the chemovar for a given cannabis strain. As used herein the term “chemovar” means the cannabinoids and terpenes beyond the major ones, plus any other elements that is not inert, contributes to the overall user experience.

[0008] A key challenge herein lies in how to accurately quantify a user experience profile associated with a particular cannabis strain. Firstly, most of what is known about cannabinoids and terpenes is a result of studying their properties in isolation. These approaches are too simplistic to generalize the real world results of the user experience. For example, in the real world, a user does not consume isolated a-pinene and wait to see how much it improves the pine aroma. Alternatively, metabolomics approach combining detailed chemical composition data analysis based on gas chromatography analysis of major terpenes and cannabinoids have been used to map the current chemical diversity of cannabis strains (see Hazekamp, A., et al., Cannabis and Cannabinoid Research, Vol. 1.1, 2016). However, these approaches merely provide chemical analysis intended for development of a classification system for the variety of cannabis strains.

[0009] Secondly, cannabis chemotyping based on their suite of chemical constituents have focused largely on cannabinoids THC and CBD, particularly the overall amount of THC produced and on the ratio of THC to CBD. Since the popularization of the concept of “entourage effect”, cannabis chemotyping also includes secondary compounds (i.e., terpenes) beyond THC and CBD with the ability to influence the user experience. Efforts to characterize the user experience according to terpene profile have relied on analytical data predominately to chemically profile the strains. It is doubtful that any meaningful conclusion to the real world user experience can be obtained from such an approach. That is because current reporting systems are simply “data dumps” that present raw data regarding the absolute or relative contents of terpenes and cannabinoids, but make no attempt to correlate it to the physiological, psychoactive or sensorial effects experienced by the consumer.

[0010] While these methods to define the unique user experience profile of a particular cannabis strain have been made, there have been reports of inconsistent results, for example, in terms of fidelity to the original user experience and/or organoleptic properties obtained with such approaches. As such these methods still have limitations and do not allow for an accurate quantification of the unique user experience profile associated with a particular cannabis strain.

[0011] Therefore, there still remains a need for an improved method for quantifying the unique user experience profile for a particular cannabis strain. In particular, it is desirable that the improved method provides a more accurate user experience profile based on the cannabinoids and terpenes beyond the major ones and their effects on the overall user experience. There is also a need for a method to formulate a cannabinoid composition and/or enhance the unique user experience profile base on the quantified user experience profile.

SUMMARY

[0012] This Summary is provided to introduce a selection of concepts in a simplified form that are further described below in the Detailed Description. This Summary is not intended to identify key aspects or essential aspects of the claimed subject matter.

[0013] The inventors have developed a proprietary method that is surprisingly accurate in terms of quantifying the unique user experience profile associated with a cannabis strain based on the physiological, psychological and/or sensorial effects attributable to the cannabinoids and terpenes. Advantageously, the herein described method provides a user experience profile of the cannabis strain that may be useful to recreate a more consistent user experience to the original (i.e., known) user experience from the cannabis strain. The method according to the present disclosure also provides a user experience profile that may be used to enhance the user experience, specifically, by formulating with a subset of cannabinoids and/or terpenes that focus on those cannabinoids and/or terpenes that provide the desired effects. In essence, the present method takes raw cannabinoid and terpene data and correlates it to the physiological, psychological and/or sensorial effects they supposedly cause. The method according to the present disclosure thereby transforms the raw cannabinoid and terpene data into information useful for quantifying a user experience profile.

[0014] As embodied and broadly described herein, the present disclosure relates to a method of quantifying a user experience associated with a cannabis strain comprising: a) selecting a cannabis strain having a known user experience profile; b) determining one or more user experience characteristics of the cannabis strain as measured by descriptive analysis (DA); c) assessing the presence and levels of cannabinoids and/or terpenes from the cannabis strain by analytical analysis (AA); and d) correlating the presence and levels of cannabinoids and/or terpenes from the analytical analysis (AA) to results of the descriptive analysis (DA) to generate a quantified user experience profile associated with the cannabis strain.

[0015] As embodied and broadly described herein, the present disclosure also relates to a system comprising: a) an input of one or more user experience characteristics of a cannabis strain as measured by descriptive analysis (DA) from one or more subjects, wherein each of the user experience characteristic is generated based on at least one or more of: (i) an organoleptic effect, (ii) a physiological effect, or (iii) psychoactive effects; b) a chemical analyzer configured to: (i) receive a cannabis strain having a known user experience profile, the cannabis strain comprising one or more terpenes and/or one or more cannabinoids; and (ii) chemically analyze the cannabis strain to determine the presence and levels of the one or more terpenes and/or cannabinoids by analytical analysis (AA); and c) a computer-implemented correlator for correlating the presence and levels of the terpenes and/or cannabinoids from the analytical analysis (AA) to results of the descriptive analysis (DA) to generate a quantified user experience profile associated with the cannabis strain.

[0016] As embodied and broadly described herein, the present disclosure also relates to a method for formulating a cannabinoid composition having a user experience profile as comparable to a known user experience profile of a cannabis strain, the method comprises: a) receiving a quantified user experience profile as defined herein; b) selecting cannabinoids and/or terpenes based on the quantified user experience profile; and c) forming the cannabinoid composition, wherein the cannabinoid composition comprises cannabinoids and/or terpenes at levels similar to cannabinoids and/or terpenes present in the quantified user experience profile.

[0017] As embodied and broadly described herein, the present disclosure also relates to a cannabinoid composition formulated according to the method as defined herein, and having a user experience that is similar, preferably substantially similar, to the known user experience profile associated with the cannabis strain.

[0018] As embodied and broadly described herein, the present disclosure also relates to a method of formulating a modified cannabinoid composition having an enhanced user experience as comparable to a known user experience profile of a cannabis strain, the method comprising: a) receiving a quantified user experience profile as defined herein; b) selecting cannabinoids and/or terpenes matched to their relative contributions to the desired user experience characteristics of the quantified user experience profile; and c) forming the cannabinoid composition, wherein the cannabinoid composition comprises subsets of cannabinoids and/or terpenes at levels dissimilar to cannabinoids and/or terpenes present in the quantified user experience profile.

[0019] As embodied and broadly described herein, the present disclosure also relates to a cannabinoid composition comprising a modified cannabinoid profile, wherein the modified cannabinoid profile comprises dominant cannabinoids and non-dominant cannabinoids present in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification.

[0020] As embodied and broadly described herein, the present disclosure also relates to a cannabinoid composition comprising a modified terpene profile, wherein the modified terpene profile comprises dominant terpenes and non-dominant terpenes present in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification.

[0021] As embodied and broadly described herein, the present disclosure also relates to a cannabinoid composition comprising a modified terpene profile comprising dominant terpenes and non-dominant terpenes and a modified cannabinoid profile comprising dominant cannabinoids and non-dominant cannabinoids, wherein the terpenes and the cannabinoids are present in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification.

[0022] As embodied and broadly described herein, the present disclosure also relates to a method of formulating a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified cannabinoid profile as defined herein; and b) selecting dominant and non-dominant cannabinoids based on the modified cannabinoid profile. [0023] As embodied and broadly described herein, the present disclosure also relates to a method of formulating a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified terpene profile as defined herein; and b) selecting dominant and non-dominant terpenes based on the modified terpene profile.

[0024] As embodied and broadly described herein, the present disclosure also relates to a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified cannabinoid profile and a modified terpene profile as defined herein; b) selecting dominant and non-dominant cannabinoids based on the modified cannabinoid profile; and c) selecting dominant and non-dominant terpenes based on the modified terpene profile.

[0025] As embodied and broadly described herein, the present disclosure also relates to a cannabinoid product comprising the cannabinoid composition as defined herein.

[0026] As embodied and broadly described herein, the present disclosure also relates to a method of enhancing a user experience of a cannabinoid product comprising preparing the cannabinoid product as defined herein.

[0027] As embodied and broadly described herein, the present disclosure also relates to a cannabinoid product comprising the cannabinoid composition as defined herein.

[0028] All features of exemplary embodiments which are described in this disclosure and are not mutually exclusive can be combined with one another. Elements of one embodiment can be utilized in the other embodiments without further mention. Other aspects and features of the present disclosure will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments in conjunction with the accompanying Figure.

BRIEF DESCRIPTION OF THE DRAWINGS

[0029] While the specification concludes with claims particularly pointing out and distinctly claiming the invention, it is believed that the invention will be better understood from the following description of the accompanying figure wherein like numerals are employed to designate like parts throughout the same. [0030] Figure 1 shows an embodiment of a system for quantifying the user experience profile according to the present disclosure.

DETAILED DESCRIPTION

Definition

[0031] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by a person of ordinary skill in the art to which the present invention pertains. As used herein, and unless stated otherwise or required otherwise by context, each of the following terms shall have the definition set forth below.

[0032] As used herein, terms of degree such as “about”, “approximately” and “substantially” mean a reasonable amount of deviation of the modified term such that the end result is not significantly changed. These terms may refer to a measurable value such as an amount, a temporal duration, and the like, and are meant to encompass variations of +/- 0.1% of the given value, preferably +/- 0.5%, preferably +/- 1%, preferably +/- 2%, preferably +/- 5% or preferably +/- 10%.

[0033] As used herein, articles such as “a” and “an”, are understood to mean one or more of what is claimed or described.

[0034] As used herein, the terms “comprises”, “comprising”, “include”, “includes”, “including”, “contain”, “contains” and “containing” are meant to be non-limiting, i.e., other steps and other sections which do not affect the end of result can be added. The above terms encompass the terms “consisting of’ and “consisting essentially of’.

[0035] As used herein, the term “cannabinoid composition” means a liquid or solid composition comprising an effective amount of a cannabinoid to deliver the desired user experience profile. In some embodiments, this involves recreating a known user experience associated with a particular cannabis strain based on the quantified user experience profile. In some embodiments, the cannabinoid composition may be formulated for oral or nasal administration.

[0036] As used herein, the term “consumer(s)” is used in the broadest sense and is a mammal, usually human, that includes but is not limited to a consumer, a user, a beneficiary or an observer. A consumer can also be involved in a test (real world or simulation) whereas he/she may also be called a panelist or panelist, preferably a trained panelist. In some embodiments of the present disclosure, the consumer is an observer of another person who is using or consuming the cannabis strain.

[0037] As used herein, the term “modified cannabinoid composition” means a cannabinoid composition as defined herein, wherein the terpene profile and/or the cannabinoid profile has been modified in order to enhance the user experience as compared to the known (i.e.. original) user experience associated with the cannabis strain. By modifying the terpene profile and/or the cannabinoid profile, it is desired that select effects attributable to the terpenes and/or cannabinoids, preferably from the non-dominant terpenes and/or non-dominant cannabinoids, can be perceived by the user or perceived to a greater extent in terms of, for example, with greater intensity, over a longer period of time, or with enhanced character.

[0038] As used herein, the term “cannabinoid profile” refers to the number, identity and quantity of cannabinoids in a sample. In some embodiments, cannabinoid compositions of the disclosure generally contain a blend of at least 2, at least 3, at least 4, at least 5, at least 7, at least 10, at least 15 or at least 20 cannabinoids. The cannabinoid profile may comprise dominant cannabinoids, non-dominant cannabinoids or both. In some embodiments, the cannabinoid profile may reflect the relative ratio of cannabinoids to each other present in the sample. The relative intensity (i.e.. strength) and/or relative concentration of each cannabinoid of the cannabinoid profile may be assessed, for example, in regards to its contribution to the physiological effect and/or psychoactive effect.

[0039] As used herein, the term “cannabis strain” refers to the plant genus cannabis, including different varieties such as for example, cannabis saliva, cannabis indica, and cannabis ruderalis. Different varieties of the cannabis strains often exhibit distinct chemical compositions with characteristic levels of cannabinoids and terpenes, as well as other components. These differences account for the unique user experience associated with the different varieties of the cannabis strains. The cannabis strain may include any member of naturally occurring and synthetic cannabinoids and terpenes, and extracts from any cannabis species and varieties. Preferably, the cannabis strain is a natural cannabis strain.

[0040] As used herein, the term “descriptive analysis (DA)” refers to sensory methods by which one or more user experience characteristics ( e.g ., organoleptic, physiological, or psychoactive) are identified and quantified. In some embodiments, the measures of the aroma or flavor of the cannabis samples include sensory attribute metrics such as those measured using quantitative descriptive analysis (DA) techniques. For example aroma and flavor can be reliably and reproducibly measured using sensory analysis methods known as descriptive analysis (DA) techniques (see Morten Meilgaard, D. Sc. et al., Sensory Evaluation Techniques (3^rd ed. 1999). Suitable examples of the descriptive analysis (DA) method are provided herein below.

[0041] As used herein, the term “extract” refers to a composition obtained by extracting a raw material, using a solvent system. The expression “an extract of the cannabis strain” refers to a composition obtained by extracting cannabis (or any part thereof). In some embodiments, the process of extracting a raw material using a solvent includes a hot solvent extraction. In some embodiments, the process of extracting a raw material using a solvent includes supercritical fluid extraction (FSFE). In some embodiments, the process of extracting a raw material retains a substantial portion of the cannabinoids and/or terpenes present in the cannabis strain. Some non-limiting examples may include, hash oil, tincture, or a combination thereof.

[0042] As used herein, the term “organoleptic effect” refers to perceivable sensorial effects on the users, such as aroma and flavor, at any moment in time during or after consumption of cannabis containing compositions or elements or components of cannabis. The organoleptic effect may change over time.

[0043] As used herein, the term “physiological effect” refers to the effect on the body of a user after consumption of cannabis containing compositions or elements or components of cannabis. Non-limiting examples of physiological effects may include changes in appetite, dry mouth, red eyes, impaired motor skills, elimination of certain types of pain, decrease in muscle spasms, suppression of nausea, relief of eye pressure, or cessation of convulsions. The nature and type of the physiological effects do not warrant a more detailed description here, which the skilled person would be able to detect on the basis of her common general knowledge and the cannabis strain, and according to the intended effects and the known user experience profde associated with the cannabis strain.

[0044] As used herein, the words “preferred”, “preferably” and variants refer to embodiments of the disclosure that afford certain benefits, under certain circumstances. However, other embodiments may also be preferred, under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful, and is not intended to exclude other embodiments from the scope of the disclosure.

[0045] As used herein, the term “psychoactive effect” refers to the effect, preferably significant effect, to the mind or mental processes of a user upon consumption of cannabis containing compositions or elements or components of cannabis. Psychoactive effect may change brain function and/or result in alterations in perception, mood, consciousness, cognition or behavior. [0046] As used herein, the term “terpene” refers to both terpenes and terpenoids, which are a large and diverse class of organic compounds, produced by a variety of cannabis plants. Typically known for their organoleptic effects, they are commonly used in the manufacture of edible products (e.g., gum, candies, mints) and fragrances. They are also recognized as entourage compounds meaning they modulate (e.g., enhance) the effects of the cannabinoids.

[0047] As used herein, the term “terpene profile” refers to the number, identity and quantity of terpenes found in a sample. The terpene profile may comprise dominant terpenes, non-dominant terpenes or both. In some embodiments, the terpene profile may reflect the relative ratio of terpenes to each other present in the sample. The relative intensity (i.e., strength) and/or relative concentration of each terpene of the terpene profile may be assessed, for example, in regards to its contribution to the organoleptic effect (e.g., aroma and/or flavor) of the individual terpenes. The relative intensity (i.e., strength) and/or relative concentration of each terpene of the terpene profile may also be assessed, in combination with the organoleptic effect or independently in regards to its contribution to the physiological effect, and/or psychoactive effect.

[0048] As used herein, the term “user experience” refers to the characteristic experience with respect to certain variables, such as for example the organoleptic effect, physiological effect, and/or psychoactive effect, after consuming cannabis containing compositions, or elements or components of the cannabis. In some embodiments, the “user experience” refers to at least one of these variables.

[0049] As used herein, the term “user experience characteristics” refer to the user experience, as defined above, as assessed using descriptive analysis (DA) as provided herein.

[0050] As used herein, the term “user experience profile” refers to the totality of the organoleptic effect, physiological effect, and psychoactive effect that a user can experience while consuming the cannabis containing compositions, or elements or components of the cannabis.

[0051] As used herein, the term “known user experience profile” refers to the real world user experience profile that is commonly associated with consumption of a particular cannabis strain.

[0052] As used herein, “quantified user experience profile” refers to a user experience profile generated from the method according to the present disclosure. Preferably, the quantified user experience profile may closely resemble the known user experience profile of the cannabis strain that was subjected to the method. [0053] In all embodiments of the present disclosure, all percentages, parts and ratios are based upon the total weight of the compositions of the present disclosure, unless otherwise specified. All such weights as they pertain to listed ingredients are based on the active level and, therefore do not include solvents or by products that may be included in commercially available materials, unless otherwise specified.

[0054] All ratios are weight ratios unless specifically stated otherwise. All temperatures are in Celsius degrees (°C), unless specifically stated otherwise. All dimensions and values disclosed herein (e.g., quantities, percentages, portions, and proportions) are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension or value is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40mm” is intended to mean “about 40 mm.”

[0055] Note that titles or subtitles may be used throughout the present disclosure for convenience of a reader, but in no way these should limit the scope of the invention. Moreover, certain theories may be proposed and disclosed herein; however, in no way they, whether they are right or wrong, should limit the scope of the invention so long as the invention is practiced according to the present disclosure without regard for any particular theory or scheme of action.

[0056] Elements of the composition of the disclosure described in connexion with the examples apply mutatis mutandis to other aspects of the disclosure. Therefore, it goes without saying that the compositions of the present disclosure encompasses any composition comprising any of the ingredients cited herein, in any embodiment wherein each such ingredient is independently present in any appropriate amount as defined herein. Many such compositions, than what is specifically set out herein, can be encompassed.

Method of Quantifying the User Experience Profile of Cannabis

[0057] The inventors have surprisingly discovered a revolutionary new way of quantifying a unique user experience profile associated with a particular cannabis strain that may be able to address the problems as discussed above. Essentially, the solution is to integrate sensory experiences as perceived by users using quantitative descriptive analysis (DA) techniques to more accurately capture the real world effects attributable to the cannabinoids and/or terpenes profile.

[0058] Specifically, in one aspect, the present disclosure provides for a method of quantifying a user experience associated with a cannabis strain, the method comprising: a) selecting a cannabis strain having a known user experience profile; b) determining one or more user experience characteristics of the cannabis strain as measured by descriptive analysis (DA); c) assessing the presence and levels of cannabinoids and/or terpenes from the cannabis strain by analytical analysis (AA); and d) correlating the presence and levels of the cannabinoids and/or terpenes from the analytical analysis (AA) to results of the descriptive analysis (DA) to generate a quantified user experience profile associated with the cannabis strain.

[0059] The method according to the present disclosure comprises in step a) the selection of a known user experience profile associated with a particular cannabis strain. The purpose is to select a cannabis strain that has a desirable known user experience profile. There are literally thousands of varieties of cannabis strains to choose from, each with a unique chemovar and associated user experience profile. These user experience profiles associated with the cannabis strains are known in the art or readily available on-line and can be obtained from a variety of websites, such as for example, https ://www .leafly.com/strains/. The consumers can refer to these types of websites to leam more about the cannabis strain and obtain information from reviews left by other consumers. It will be appreciated that the selection of a known user experience profile may be based on, for example, a consumer survey of the commercially successful or favorite cannabis strains.

[0060] Some popular cannabis strain may include, for example, “Sour Diesel” which is known for fighting depression and anxiety. In particular, Sour Diesel is known for its energizing and stress-relieving effects and having diesel, lemon, oaky, sour and earthy aroma and flavors ( see Table 1). Another example is the cannabis strain labelled “Pineapple Express”, which is quite popular and known to smell like fresh apple, mango and pineapple. Pineapple Express is known to provide a long -lasting energetic buzz ideal for creative escapes (see Table 1). Other suitable examples of cannabis strain are readily known to the skilled person or may also be found, for example, at paragraph [0077] of US 2018/0369192.

[0061] It is an advantage of the method of the present disclosure to more accurately quantify the unique user experience profile, such that it will provide a sensory map of existing chemovars, particularly of the more popular cannabis strains. With this information, the Applicant is able to identify opportunities (i.e.. white space) on the map for new chemovars. It is yet a further advantage of the present disclosure to be able to create an enhanced user experience, such as for example, new to the world user experience profile wherein one, or several, of the organoleptic, physiological, and/or psychoactive effects, are selectively modified to provide a customizable user experience that is desired.

[0062] Step b) of the method involves the use of descriptive analysis (DA) to characterize one or more of the user experience characteristics. Essentially, the inventors have discovered that this type of descriptive analysis (DA) techniques allows for the development of customizable terminology to more accurately quantify the user experience characteristics of interest and correlate these results to the presence and levels of the cannabinoids and/or terpenes associated obtained by analytical analysis (AA) for a particular cannabis strain. Advantageously, by using descriptive analysis (DA), the herein described method provides results that are more realistic and/or representative of the user experience profile, which makes the data more valuable than with analytical analysis (AA) techniques alone and/or traditional sensory methods.

[0063] In some embodiments of the present disclosure, to minimize the subjectivity of the effects experienced by users who have experienced the cannabis products, it is preferable that the descriptive analysis (DA) involves using a consumer who has been specifically chosen and trained for this purpose. It would be understood that the trained consumer may function as a human analytical instrument, generating more realistic and reproducible results, rather than mere degrees of liking or disliking as commonly found in traditional sensory methods with untrained consumers. Descriptive analysis (DA) may involve specifically choosing sensory attributes perceived by the users that are to be identified and quantified for the purpose of mirroring the real world user experience for that particular cannabis strain.

[0064] In some embodiments of the present disclosure, the user experience characteristics are measured by the descriptive analysis (DA) using sensory analysis to evaluate 1 or more descriptors selected from the group consisting of an organoleptic effect, a physiological effect and a psychoactive effect. It is preferable that the sensory analysis involves at least 2 or more descriptors, or preferably all 3 descriptors. When the descriptive analysis (DA) involves the organoleptic effect, it typically involves the analysis of the aroma, the flavor or both, preferably the descriptive analysis (DA) in this case would involve both profdes.

[0065] In some embodiments of the present disclosure, the organoleptic effect may be characterized by the 'intensity' and/or 'character' of the aroma profde or flavor profde. The 'intensity' relates to the perceived strength of the aroma or flavor, whilst 'character' refers to the aroma or flavor impression of the cannabis sample. Non-limiting examples of aroma descriptors of the organoleptic effects are provided in Table 2. Table 2 - Aroma Descriptors of Organoleptic Effects of Cannabis ammonia diesel mint skunk apple earthy nutty spicy apricot flowery orange strawberry berry grape peach sweet blue cheese grapefruit pear tar blueberry herbal pepper tea butter honey pine tobacco cheese lavender pineapple tree fruit chemical lemon plum tropical fruit chestnut lime pungent vanilla citrus mango rose violet coffee menthol sage woody

[0066] Non-limiting examples of flavor descriptors of the organoleptic effects are provided in Table 3.

Table 3 - Flavor Descriptors of Organoleptic Effects of Cannabis

[0067] These aroma and flavor descriptors are compiled from Flavomet (available from: <http://flavornet.org/flavornet.html>, accessed October 10, 2019) and/or The Good Scents Company (available from: <http://www/thegoodscentscompany.com/index.html>, accessed October 10, 2019). Flavomet has aroma descriptors for over 700 compounds, compiled from studies using GC -olfactometry (T.E. Acree, H. Am, Flavomet and human odor space (2004)). The Good Scents Company provides organoleptic information to the flavor, food and fragrance industry. It will be understood by those skilled in the art that the method according to the present disclosure would not be limited to these specific aroma and/or flavor descriptors as disclosed in Tables 3 and 4. Other suitable examples of aroma or flavor descriptors can be used and still fall within the scope of the present disclosure.

[0068] In some embodiments of the present disclosure, the descriptive analysis (DA) attribute may be the aroma of the cannabis strain. Preferably, the organoleptic effect of the present disclosure may be an aroma having an aroma intensity rating attributable to the cannabis strain as measured by the descriptive analysis (DA). In some embodiments, the aroma may be measured by panelists. Preferably, the panelists involve with a test on aroma intensity first participate in a training session to familiarize themselves with a reference sample (i.e., the intended aroma) and practice scoring aroma intensity. For example, the panelists are asked to score the aroma intensity of a reference sample on a scale from 0 to 15, with 0 being “none” and 15 being “very strong” based on the aroma descriptors, for example, provided in Table 2. Although a scale of 0 to 15 is provided, it is intended for illustrative purposes only and other ranges are permissible and would fall within the scope of the present invention.

[0069] Trained panelists represent individuals who have adequately familiarized themselves with the aroma descriptors. For example, if the intended aroma is orange, then the panelists will be presented with a reference sample that only has orange aroma and asked to score the type and intensity of the perceived aroma. The training is repeated until the panelists have correctly identified the aroma and its relative intensity. According to this embodiment, once qualified, the trained panelists (e.g., 5 or 10) are then asked to score the aroma intensity of test samples based on the aroma descriptors, such as for example, as provided in Table 2. Typically, for the test, the trained panelists are directed to smell the sample for a sufficient amount of time (e.g., about 3-5 seconds) and within close enough proximity (e.g., about 2-5 cm) in order to make the assessment, and then evaluate the type and intensity of the aroma. The aroma descriptors may be provided to the panelists or the panelist may be asked to identify the aroma descriptors from a list. In one aspect of this embodiment, the trained panelists may consume (e.g., ingest) the cannabis strain and inhale the aroma during consumption. In another aspect of this embodiment, the trained panelists may merely inhale the aroma from the cannabis strain, which may have been combusted. The trained panelists may be asked to repeat the steps at subsequent time points (e.g., 8 seconds, 10 seconds, 12 seconds, etc. after ingestion and/or inhalation) to characterize the aroma as it evolves over time. It is preferred that the trained panelists are not exposed to more than 3 different samples in any test session. If the trained panelists participate in 2 or more test session per day, then an hour break between each session should be provided. [0070] Alternatively, in some embodiments, the organoleptic effect of the present disclosure may be assessed by determining the odor activity value (OAV) of a terpene attributable to the cannabis strain as measured by the descriptive analysis (DA) . OAV is defined as the ratio of the terpenes present in the sample to the odor detection threshold (ODT) for that particular terpene, in dimensionless units. As used herein, the term “odor detection threshold” refers to the lowest vapor concentration of the terpene which can be olfactorily detected. Published ODTs for common terpenes present in cannabis are readily available (see for example Rice, S., et al., Forensic Science International, 257, 257-270 (2015)).

[0071] In some embodiments of the present disclosure, the aroma may be measured by an electronic nose (i.e., synthetic nasal device). Use of an electronic nose is desirable as its will quantify the aroma in a less subjective manner. See for example, WO 2009/053981, US 2014/0096590, Cyranose.RTM. 320, Sensigent, Baldwin Park, Calif.; Arshak et al. (2004) Sensor Review. 24:181-198; Monge et al. (2004) Comb. Chem. High Throughput Screen. 7:337-344; Ye etal (2011 )J. Pharm. Biomed. 55: 1239-1244; Hodgins et al (1995) J. Automat. Chem. 17: 179-185. The electronic nose may be trained such that it will recognize the aroma based on the descriptors, such as for example, provided in Table 3 and its intensity. The method comprises providing a test sample containing an olfactorily detectable quantity of the composition in the atmosphere, and causing an electronic nose to detect the presence and/or intensity of the aroma.

[0072] In some embodiments of the present disclosure, the descriptive analysis (DA) attribute may be the flavor of the cannabis strain. Preferably, the organoleptic effect of the present disclosure may be a flavor having a flavor impression rating attributable to the cannabis strain as measured by descriptive analysis (DA). In some embodiments, the flavor may be measured by panelists. Preferably, the panelists involved with a test on flavor impression may first participate in training session to familiarize themselves with a reference sample (i.e., the intended flavor) and practice scoring flavor impression intensity. For example, the panelists are asked to score the flavor intensity of a reference sample on a scale from 0 to 15, with 0 being “none” and 15 being “very strong” based on taste descriptors, for example, based on the ones provided in Table 3. Although a scale of 0 to 15 is provided, it is intended for illustrative purposes only and other ranges are permissible and would fall within the scope of the present invention.

[0073] Trained panelists represent individuals who have adequately familiarized themselves with the flavor descriptors. For example, if the intended flavor is menthol, then the panelists will be presented with a reference sample that only has menthol flavor and asked to score the type and intensity of the perceived flavor. The training is repeated until the panelists have correctly identified the flavors. According to this embodiment, once qualified, the trained panelists (e.g., 5 or 10) are then asked to score the flavor intensity of test samples based on the flavor descriptors as provided, such as for example, in Table 3. Typically, for the test, the trained panelists are directed to taste the sample for a sufficient amount of time (e.g., about 3- 5 seconds) in order to make the assessment, and then evaluate the type and/or intensity of the flavor. The flavor descriptors may be provided to the panelists or the panelists may be asked to identify the flavor descriptors from a list.

[0074] In some embodiments of the present disclosure, the flavor may be more objectively measured by an electronic tongue. Common types of sensors used are based on electrochemical techniques, such as potentiometry and voltammetry; piezoelectric crystals (e.g., Piezoelectric Quartz Crystal (PQC); see US 8,004,152), Wolf et ak, CZ 294443; Ashlers, DE 10315848; Winquist et ah, WO 2002/052254; and technology using Molecularly Imprinted Polymer (MIP) for taste assessment in drink, beverages or food products. MIP technology may provide for recognition of flavor molecules, for example, by re-arranging monomers with desirable chemical function groups to mimic the function of a taste bud(s). A MIP -PQC sensor array provides results comparable to taste assessment from qualified panelists. The electronic tongue may be trained such that it will recognize the flavor based on the descriptors provided, such as for example, in Table 3 and its intensity. The method comprises providing a test sample containing a detectable quantity of a flavorant in the composition, and causing an electronic tongue to detect the presence and intensity of the flavorant.

[0075] In some embodiments of the present disclosure, the descriptive analysis (DA) attribute may involve the physiological effect of the cannabis strain. Preferably, the physiological effect of the present disclosure may have a physiological effect intensity rating attributable to the cannabis strain as measured by descriptive analysis (DA). The physiological effect intensity rating may be assessed by collecting a physiological measurement, a body language measurement or both from the consumer. For the purposes of clarification, the terms “physiological measurement” and “biometric data” are used interchangeably herein. Suitable examples of “biometric data” are disclosed in: US 5,676,138; US 6,190,314; US 6,309,342; US 7,249,603; and US 2005/0289582. “Body language measures” measure both the autonomic responses of the consumer, as well as learned responses whether executed consciously or sub-consciously, often executed as learned habit. “Body language measures”, among other things, can also include non-verbal communicative emotive states such as body gestures, postures, body and/or facial expressions (e.g., winking or slight movement of the eyebrows), and the like. Other suitable non-limiting examples of body language measures are disclosed in: US 2005/0289582; US 5,436,638; and US 7,227,976. [0076] The method according to the present disclosure aims to quantify the physiological effects according to the physiological measurements, body language measures or both. Generally, physiological measurements measure changes or indications in body temperature, e.g., measured by conductive or infrared thermometry, facial blood flow, skin impedance, EEG, EKG, blood pressure, blood transit time, increase heart rate, peripheral blood flow, perspiration or sweat, SDN heart rate variability, galvanic skin response, pupil dilation, respiratory pace and volume per breath or an average taken, digestive tract peristalsis, large intestinal motility, and piloerection, i. e. , goose bumps or body hair erectile state, saccades, temperature biofeedback, among others (e.g., US 2007/010066). Physiological measurements may also include body temperature (conductive or IR thermometry), facial blood flow, skin impedance, qEEG (quantified electroencephalography), stomach motility, and body hair erectile state, among others. Additional physiological measurements can be taken such as a facial electromyography, saliva viscosity and volume, measurement of salivary amylase activity, body metabolism, brain activity location and intensity, i. e. , measured by fMRI or EEG.

[0077] In some embodiments, biometric data comprises cardiac data. Cardio vascular monitoring and other cardiac data obtaining techniques are described in US 2003/0149344 (e.g., more rapid breathing). A commercial monitor may include the TANITA™, 6102 cardio pulse meter. Electro-cardiography, (using a Holter monitor) is another approach. Yet another approach is to employ UWB radar.

[0078] In some embodiments, the biometric data is ocular biometric data. Ocular biometric data is data obtained from the consumer’s eye during research. Examples may include pupil dilation, and blink and/or eye tracking data.

[0079] Additional physiological measurements can be taken such as: electromyography of the facial, or other muscles; saliva viscosity and volume measures; measurement of salivary production; body biological function, e.g., metabolism via blood analysis, urine or saliva sample in order to evaluate changes in nervous system-directed responses, e.g., chemical markers can be measured for physiological data relating to levels of neuro-endocrine or endocrine-released hormones; brain function activity. Brain function activity (e.g., location and intensity) may be measured by fMRI, a form of medical imaging in this case directed toward the brain. A non-exhaustive list of medical imaging technologies that may be useful for brain function activity understanding, (but can be used for observing other physiological metrics such as the use of ultrasound for heart or lung movement), include fMRI (functional magnetic resonance imaging), MRI magnetic resonance imaging), radiography, fluoroscopy, CT (computed tomography), ultrasonography, nuclear medicine, PET (Positron emission tomography), OT (optical topography), NIRS (near infrared spectroscopy) such as in oximetry, and fNIR (functional near-infrared imaging).

[0080] Another example of monitoring brain function activity data may include the “brain-machine interface” developed by Hitachi, Inc., measuring brain blood flow. Yet another example includes “NIRS” or near infrared spectroscopy. Yet still another example is electroencephalography (EEG). See also e.g., US 6,572,562.

[0081] It should be appreciated that body language changes and measurements include all facial expressions, e.g., monitoring mouth, eye, neck, and jaw muscles, voluntary and involuntary muscle contractions, tissue, cartilage, bone structure, body limb positioning and gestural activity, limb motion patterns, e.g. , tapping, patterned head movements, e.g. , rotating or nodding, head positioning relative to the body and relative to the applied stimulus, vocal cord tension and resulting tonality, vocal volume (decibels), and speed of speech. When monitoring body language such as facial expressions (e.g., smiling, giggling) or vocal changes (e.g. chattiness, volume, logic), a non-invasive apparatus and method can be used. For example, a video digital photography apparatus can be used that correlates any facial expression changes with facial elements analysis software, or the Facial Action Coding System by Ekman at: http://face-and- emotion.com/dataface/facs/description.jsp or www .paulekman.com. See e.g., US 2003/0032890.

[0082] In one aspect of the method of the present disclosure, the biometric data may be obtained from the consumer at different time points post consumption of the cannabis strain. For example, the consumer’s pulse rate can be taken after consumption of the cannabis strain at different time points post consumption. The measured data from the physiological and body language assessment are later correlated to the cannabinoid levels present in the consumer at those various time points.

[0083] In some embodiments of the present disclosure, the descriptive analysis (DA) attribute may involve assessment of the psychoactive effect of the cannabis strain. Preferably, the psychoactive effect may have a psychoactive effect intensity rating attributable to the cannabis strain as measured by the descriptive analysis (DA). One difficulty in measuring psychoactive effect comes from the lack of a concise definition for what constitutes a “psychoactive effect”, as it tends to be more diffused. Another difficulty is the complexity of the human response to cannabis and that ever person’s psychological response may be different and can change over time.

[0084] Traditionally, assessment of psychoactive effect involves a rather simplistic approach whereby the user is asked to rate her “experience” (i.e., high) on a scale from 0 to 10, with “0” equaling very weak/bad high and “10” meaning a really strong/good high. The drawback to such a simplistic approach is that it cannot distinguish between different psychoactive effects, or decouple the intensity/strength rating from the character (i.e.. type of psychoactive effects).

[0085] The method according to the present disclosure attempts to quantify the psychoactive effects according to the elicited moods. In particular, the method utilizes mood descriptors that more accurately characterize the psychoactive effects and/or differentiates between the different psychoactive effects experienced by the user. Therefore, instead of the generic “high”, more specific mood descriptors are employed. Non-limiting examples of suitable mood descriptors are provided in Table 4.

Table 4 - Mood Descriptors of Psvchoactive Effects of Cannabis

[0086] The mood descriptors are based on the UWIST Mood Adjective Checklist (UMAC, Matthews, Jones & Chamberlain, 1990) and/or the Brief Mood Introspection Scale (BMIS, Mayer & Gaschke, 1988), and modified as appropriate by the inventors to capture unique elicited moods specific to cannabis use. For example, “euphoria” represents the intense feeling of well-being or happiness (i.e., an uplifted mood), and “relaxation” represents the feeling of being free from tension and anxiety. While both of these mood descriptors represent possible psychoactive effects, the user experiences associated with each of them are different. It will be understood by those skilled in the art that the method according to the present disclosure is not limited to these specific mood descriptors as provided herein.

[0087] In some embodiments, panelists involve with a test on psychoactive effects may participate in a training session to first familiarize themselves with a reference sample (i.e., the intended mood) and practice scoring mood intensity. The intended mood is provided by using a cannabis strain that is known to elicit the desired psychoactive effect. The mood intensity can be scored, for example, on a scale from 0 to 15, with 0 being no impact and 15 being very strong impact based on the mood descriptors, for example, provided in Table 5. Although a scale of 0 to 15 is provided, it is intended for illustrative purposes only and other ranges are permissible and would fall within the scope of the present invention.

[0088] Trained panelists represent individuals who have adequately familiarized themselves with the mood descriptors and are able to reproducibly select the correct psychoactive effect and/or relative intensity. Advantageously, by employing trained panelists it ensures that the recorded psychoactive effect is not unique to a single subject and that the method does indeed quantify the psychoactive effect on a significant number of different individuals in a consistent and reproducible manner.

[0089] A group of the trained panelists (e.g., 5 or 10) are then asked to score the elicited moods from the test samples based on the mood descriptors as provided in Table 5 to define the cannabinoid profile associated with the particular cannabis strain. For example, the trained panelists may be asked to characterize the elicited moods at 30 seconds, 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, etc. or later post consumption (e.g., the vaping incidents). Typically, for the test, the trained panelists are directed to consume (e.g., ingest, inhale) the samples and then evaluate at least one psychological component of the consumption of the cannabis strain using the mood descriptors as described herein. For example, with a cannabis strain intended for vaping, the trained panelists may be asked to take 2, 3, 4, 5, 6 or more puffs of the samples over a span of 1 minute. Alternatively, the duration of the vaping incidents may be longer or shorter as readily determined by one skilled in the art.

[0090] It should be appreciated that multiple elicited moods can be present at the same time. For example, a cannabis strain can elicit both anxiousness and energetic, among other moods, at the same time. Therefore, in some embodiments of the present method, the trained panelists are directed to identify at least 2 at least 3 or at least 4 or more of the elicited moods. The method of the present disclosure also contemplates the trained panelists identifying all of the elicited moods experienced by the panelists.

[0091] Step c) of the method involves the use of analytical analysis (AA) techniques to chemically profile the cannabinoids and/or terpenes from a cannabis strain. In some embodiments, the method involves chemical profiling of the cannabinoids and/or terpenes from an extract of a cannabis strain. The cannabinoid profile and/or terpene profile of a sample of a cannabis strain, such as a plant, flower, fruit, leaves, etc. can be analyzed with analytical tools, such as for example, chromatography or mass spectrometry. In accordance with the embodiments, the cannabinoids and/or terpenes can be purified by any one of methodologies and techniques known in the art. Alternatively, there are contract laboratories that can purify cannabinoids and/or terpenes from samples of the natural products to provide the extract (see, e.g., Westleaf, Calgary; Sigma-Aldrich, St. Louis, Mo.; TCI America, Portland, Oreg.; Arizona Chemical, Jacksonville, Fla.).

[0092] Preferably, the cannabinoids and/or terpenes being profde from the extract are pure. Without implying any limitation, the term “pure” can refer to cannabinoids and/or terpenes that are over 90% pure, over 95% pure, over 98%, over 99% pure, over 99.5% pure, over 99.9% pure and the like. Generally, the term “pure” does not take into account any carrier oil (e.g., Medium Chain Triglycerides (MCT)) and/or solvent (e.g., ethanol, acetone, tetrahydrofuran) that may be useful for dissolving the cannabinoids and/or terpenes. Preferably, the extract retains the full-spectrum, or substantially the full-spectrum, of the cannabinoids and/or terpenes present in the cannabis strain.

[0093] In some embodiments of the present disclosure, the presence and levels of the cannabinoids and/or terpenes are assessed by chromatography, preferably gas chromatography, high performance liquid chromatography (HPLC) or other chromatographic techniques known in the art (see, e.g., Musenga el al., J. Sep. Sci. 29:1251-1258, 2006; Yang et al, J. Nat. Prod. 72:484-487, 2009; Jella et al., J. Agric. Food Chem. 46:242-247, 1998; Andrea et al., J. Agric. Food Chem. 51:4978-4983, 2003; Villa et al., J. Pharm. Biomed. Anal. 44:755-762, 2007). In some embodiments, the presence and levels of the cannabinoids are assessed by gas chromatography olfactometry-mass spectrometry (GCO-MS), gas chromatography flame ionization detector (GC-FID) or high performance liquid chromatography-mass spectrometry (HPLC-MS).

[0094] In some embodiments of the present disclosure, step d) of the method involves correlating the assessed presence and levels of the terpenes from the analytical analysis (AA) with the results of the descriptive analysis (DA), such as for example, of the organoleptic effect, including the aroma, the flavor or a combination thereof, to provide a terpene profde. In other words, the results of the descriptive analysis (DA) tests from step b) on the various parameters associated with the organoleptic effect (e.g., aroma flavor or both) are correlated to the results of the analytical analysis (AA), such as for example, the amounts or levels of the one or more terpenes relative to one another in the cannabis sample to generate the terpene profde. For example, the terpene profde may contain a listing of the different terpenes found in the sample, and their levels. The terpene profde would then reflect the relative strength of each terpene in regards to its contribution to the organoleptic effect (e.g., aroma, flavor or both) as experienced by the user.

[0095] Thus, in preferred embodiments of the present disclosure, the relative intensity (i.e., strength) and/or character of the various terpenes would be considered in making the correlation. By importing a sensory element to the quantification method, the Applicant is able to generate a quantified user experience profile linked to the aroma and/or flavor which more accurately reflects the real world effects attributable to the terpenes and not just one based on their absolute levels as found in the cannabis strain.

[0096] For example, lower levels of limonene may smell much stronger than higher levels of pinene, so therefore not only should relative levels of the various terpenes be considered, but also the relative strength of the various terpenes, particularly as they are perceived by the user. Applicant has discovered that by adopting this approach, the quantified user experience profile generated from the present method more accurately characterizes the real world user experience profile of the cannabis strain.

[0097] In some embodiments of the present disclosure, the quantified user experience profile comprises a cannabinoid profile. Preferably, step d) of the method involves correlating the assessed presence and levels of the cannabinoids from the analytical analysis (AA) to the results of the cannabinoids from the descriptive analysis (DA) of the physiological effect, the psychoactive effect or a combination thereof to provide a cannabinoid profile . Essentially the results of the descriptive analysis (DA) tests from step b) on the various parameters are then correlated to the results of the analytical analysis (AA) from step c) to generate the a cannabinoid profile that has been quantified to more accurately reflect the real world user experience associated with the cannabinoid profile of the cannabis strain.

[0098] For example, the samples are assessed for the psychoactive effects based on the elicited mood associated with the vaping incidents. The trained panelists are asked to take 5 puffs of the samples over a span of 1 minute and thereafter asked to score the elicited mood at 30 seconds, 1 minute, 2 minutes, 5 minutes, 10 minutes, and 15 minutes post the vaping incidents. The trained panelists are asked to score the “characters” (preferably at least two) of the psychoactive effects using the elicited mood descriptors, such as for example, as provided in Table 5. The trained panelists are also asked to score the “intensity” of the assessed characters based on a scale of 0 to 15, with 0 being “none” and 15 being “very strong”. The results are collected and analyzed using analysis of variance (ANOVA) to determine the psychoactive effects, which are statistically significant.

[0099] In another aspect of the present disclosure, the quantified user experience profile generated according to the method comprises a terpene profile, a cannabinoid profile or both. In some embodiments, the quantified user experience profile further comprises the psychoactive effects. Preferably, the cannabinoid profile is generated by the correlation of the presence and levels of the cannabinoids by the analytical analysis (AA) (from step c) to the results of the descriptive analysis (DA) (from step b), while the terpene profile is generated by the correlation of the presence and levels of the terpenes by the analytical analysis (AA) (from step c) to the results of the descriptive analysis (DA) (from step b).

[0100] In some embodiments of the present disclosure, the method further comprises: step e) formulating a cannabinoid composition based on the quantified user experience profile. In some embodiments of the present disclosure, the method further comprises: step f) determining that the cannabinoid composition provides the user experience that is similar, preferably substantially similar, to the known user experience profile of the cannabis strain. The quantified user experience profile generated according to the method of the present disclosure includes both analytical and sensorial measures of the user’s experience after consumption of the cannabis strain. As a result, the quantified user experience profile represents a more accurate fingerprint of the real world user experience.

[0101] In some embodiments of the present disclosure, the method further comprises: step e) formulating a modified cannabinoid composition based on the quantified user experience profile. In some embodiments of the present disclosure, the method further comprises: step f) determining that the modified cannabinoid composition provides an enhanced user experience in comparison to the known user experience profile of the cannabis strain. A modified cannabinoid composition according to the disclosed embodiments may be formed by formulating a composition having a modified terpene profile, a modified cannabinoid profile or both, to provide an enhanced user experience in comparison to the known user experience profile of the cannabis strain.

[0102] As used herein, the term “enhanced” represents the actual or perceived effect of the terpenes and/or cannabinoids that contribute to the organoleptic, psychoactive and/or physiological effects attributable to the terpenes and/or cannabinoids, preferably from the non-dominant terpenes and/or cannabinoids, to be enhanced.

[0103] In some embodiments of the present disclosure, the enhanced user experience profile associated with the modified cannabinoid composition is characterized by an aroma intensity rating that is at least 10% or greater, preferably at least 20%, or preferably at least 30% or greater as compared with that of an aroma intensity rating of an unmodified cannabinoid composition. Preferably, the aroma intensity rating is assessed at about 2 minutes, about 4 minutes, about 6 minutes, about 8 minutes, and/or about 10 minutes from the start of consumption.

[0104] In some embodiments of the present disclosure, the enhanced user experience profile associated with the modified cannabinoid composition is characterized by a flavor impression rating that is at least 10% or greater, preferably at least 20% or greater, or preferably at least 30% or greater as compared with that of a flavor impression rating of an unmodified cannabinoid composition. Preferably, the flavor intensity rating is assessed at about 2 minutes, about 4 minutes, about 6 minutes, about 8 minutes, and/or about 10 minutes from the start of consumption

[0105] In some embodiments of the present disclosure, the enhanced user experience profile associated with the modified cannabinoid composition is characterized by a physiological effect intensity rating that is at least 10% or greater, preferably at least 20% or greater, or preferably at least 30% or greater as compared with that of a physiological effect intensity rating of an unmodified cannabinoid composition. Preferably, the physiological effect intensity rating is assessed at about 2 minutes, about 4 minutes, about 6 minutes, about 8 minutes, and/or about 10 minutes from the start of consumption.

[0106] In some embodiments of the present disclosure, the enhanced user experience profile associated with the modified cannabinoid composition is characterized by a psychoactive effect intensity rating that is at least about 10% or greater, preferably at least about 20% or greater, or preferably at least about 30% or greater as compared with that of a psychoactive effect intensity rating of an unmodified cannabinoid composition. Preferably, the psychoactive effect intensity rating is assessed at about 2 minutes, about 4 minutes, about 6 minutes, about 8 minutes, and/or about 10 minutes from the start of consumption.

[0107] It will be appreciated that the cannabis strain used in the method according to the present disclosure may be a natural cannabis strain.

System for Quantifying the User Experience Profile of Cannabis

[0108] Currently, the Applicant is not aware of any systems that aid in the quantification of a user experience profile by measuring both sensorial and analytical parameters associated with consumption, preferably recreational consumption, of cannabis products. Therefore, it is an object of the present disclosure to provide a system (100) which is capable of implementing the method of quantifying a user experience associated with a cannabis strain as described herein. Figure 1 is an example of the system (100) for the generation of the quantified user experience profile associated with the cannabis strain (140). The quantified user experience profile can be constructed based on a variety of user experience characteristics and analytical measurements ofthe terpenes and cannabinoids. The system (100) comprises identifying one or more user experience characteristics to construct the quantified user experience profile. [0109] With continued reference to Figure 1, the system (100) comprises a) an input (110) of one or more user experience characteristics of a cannabis strain generated based on at least one or more of: (i) organoleptic effects (112), (ii) physiological effects (114), and (iii) psychoactive effects (116); b) a chemical analyzer (120) configured to conduct analytical analysis (AA) of the cannabis strain to determine the presence and levels of cannabinoids and/or terpenes; and c) a computer-implemented correlator (130) to correlate the presence and levels of the cannabinoids and/or terpenes from the analytical analysis (AA) to results of the descriptive analysis (DA) to generate a quantified user experience profile associated with the cannabis strain (140).

[0110] The system (100) according to the present disclosure wherein each of the user experience characteristic is generated based on input (110) from descriptive analysis (DA) measurements from each of one or more subjects of at least one or more of: (i) organoleptic effects (112), (ii) physiological effects (114), and (iii) psychoactive effects (116). Preferably, the user experience characteristic is based on descriptive analysis (DA) measurements of at least 2 of the effects, or all 3 of the effects.

[0111] The chemical analyzer (120) is configured to receive a sample of a cannabis strain having a known user experience profile (122). The sampled cannabis strain has one or more terpenes and one or more cannabinoids. It will be appreciate that it is these terpenes and cannabinoids that form the unique user experience associated with that particular cannabis strain. The chemical analyzer (120) is also configured to chemically analyze the sample to determine the presence and levels of the terpenes and/or cannabinoids (124). In some embodiments, the chemical analyzer (120) may include one or more of gas chromatography olfactometry-mass spectrometry (GCO-MS), gas chromatography flame ionization detector (GC-FID) or high performance liquid chromatography-mass spectrometry (HPLC-MS).

[0112] The computer-implemented correlator (130) is configured to correlate the presence and levels of the cannabinoids and/or terpenes to the results of the descriptive analysis (DA) to generate a quantified user experience profile associated with the cannabis strain (140). For example, the computer-implemented correlator (130) correlates the intensity and character ratings of the aroma and/or flavor from the users with the presence and levels of the cannabinoids and/or terpenes detected by the chemical analyzer (120). The computer-implemented correlator (130) may also correlate the biometric data and/or body language measures from the users with the presence and levels of the cannabinoids and/or terpenes detected by the chemical analyzer (120). A correlation between and among these components enables the generation of the quantified user experience profile that more accurately characterizes the real world user experience associated with the cannabis strain. [0113] It will be appreciated that the cannabis strain used in the system according to the present disclosure may be a natural cannabis strain.

Method of Formulating a Cannabinoid Composition

[0114] In another aspect, the present disclosure is also directed to a method to create the known user experience profile associated with a particular cannabis strain. The method enables the production of comparable cannabinoid products having high consistency to the known user experience profile associated with that particular cannabis strain. The method comprises: a) receiving a quantified user experience profile as defined herein; b) selecting cannabinoids and/or terpenes based on the quantified user experience profile; and c) forming the cannabinoid composition, wherein the cannabinoid composition comprises the cannabinoids and/or the terpenes at levels similar to cannabinoids and/or terpenes present in the quantified user experience profile.

[0115] In some embodiments of the present disclosure, the method further comprises determining that the cannabinoid composition provides the user experience that is similar, preferably substantially similar, as the known user experience profile of the cannabis strain. Preferably, the determination is performed by a trained panelist.

[0116] In another aspect, the present disclosure also encompasses a cannabinoid composition formulated according to the method as described herein and having a user experience that is similar, preferably substantially similar, to the known user experience profile associated with the cannabis strain. Preferably, the determination is performed by a trained panelist.

[0117] The legalization of recreational cannabis has brought about new users more interested in dabbling with cannabis products rather than getting blitzed. This creates a niche in the market for more customized cannabis products having an enhanced user experience profile that might be slightly different from the known user experience associated with a cannabis strain. In other words, these new users might like the user experience profile associated with a particular cannabis strain but would like to optimize one or more characteristics to enhance the user experience that may be more appropriate to their lifestyle.

[0118] As used herein, the expression “enhanced user experience” is meant to convey that a cannabinoid composition has been modified to achieve a desired change to the known user experience profile such as at least one desired, preferred or otherwise different characteristic than that of the known user experience profile. The enhanced user experience may include for non-limiting examples: lower psychoactive effects, reduce undesirable psychoactive effects, more intense aromatic or flavor qualities, or longer or shorter duration of effects.

[0119] Therefore, in yet another aspect of the present disclosure, a method of formulating a modified cannabinoid composition having an enhanced user experience as comparable to a known user experience profile of a cannabis strain is provided. The method comprises: a) receiving a quantified user experience profile as defined herein; b) selecting cannabinoids and/or terpenes matched to their relative contributions to the desired user experience characteristics of the quantified user experience profile; and c) forming the cannabinoid composition, wherein the cannabinoid composition comprises subsets of the cannabinoids and/or terpenes at levels dissimilar to cannabinoids and/or terpenes present in the quantified user experience profile. In some embodiments of the present disclosure, the method further comprises determining that the cannabinoid composition provides an enhanced user experience in comparison to the known user experience profile of the cannabis strain. Preferably, the determination is performed by a trained panelist.

[0120] A known user experience profile associated with a cannabis strain may have an undesirable or less desirable aroma and/or flavor. As a result, a user may desire a different product aroma and/or taste. The method as described herein above is the solution, as purified cannabinoids and terpenes may be incorporated into a modified cannabinoid composition having the base user experience associated with the cannabis strain, however, combined with modified levels and/or types of terpenes, such that the resultant product has the desired product aroma and/or taste profile.

[0121] In some embodiments of the present disclosure, the method of formulating a modified cannabinoid composition comprises b) selecting dominant terpenes and non-dominant terpenes matched to their relative contributions to the desired user experience characteristics of the quantified user experience profile. In other words, the selected terpenes correspond to the terpenes having the largest contributions to the organoleptic effects (e.g., aroma, flavor) as experienced by the user, rather than their levels (i.e., concentrations) as observed in the cannabis strains. Without wishing to be bound by theory, it is believed that some of the traditionally non-dominant terpenes act to provide a more noticeable and/or desired aroma and/or flavor and therefore it is desirable that they are increased relative to the dominant terpenes in the modified cannabinoid composition.

[0122] As used herein the term “dominant terpenes” refer to terpenes that are typically present at higher concentrations in the cannabis strain. In some embodiments of the present disclosure, the dominant terpenes is present from at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 98% by weight of the total amount of terpenes in said cannabis strain. Non-limiting examples of dominant terpenes may include: myrcene, a-pinene, ocimene, terpineol, b-caryophyllene, linalool, limonene, terpinolene, valencene, and geraniol. Some of the more commonly known terpenes along with their organoleptic properties are summarized in Table 5.

Table 5 - Commonly Known Terpenes

[0123] As used herein the term “non-dominant terpenes” refer to terpenes that are present at lower concentrations in the cannabis strain. In some embodiments of the present disclosure, the content of said non-dominant terpenes is present from at most about 40%, at most about 30%, at most about 20%, at most about 10%, at most about 5%, or at most about 2% by weight of the total amount of terpenes in said cannabis strain. [0124] In some embodiments of the present disclosure, the method of formulating a modified cannabinoid composition comprises b) selecting dominant cannabinoids and non-dominant cannabinoids matched to their relative contributions to the desired user experience characteristics of the quantified user experience profile. In other words, the selected cannabinoids correspond to the cannabinoids have the greatest contributions to the physiological and/or psychoactive effects as experienced by the user, rather than their levels (i.e., concentrations) as observed in the cannabis strains. Without wishing to be bound by theory, it is believed that some of the traditionally non-dominant cannabinoids act to provide a more desirable physiological and/or psychoactive effect and are therefore increased relative to the dominant cannabinoids in the modified cannabinoid composition.

[0125] As used herein the term “dominant cannabinoids” refer to cannabinoids that are typically present at higher concentrations in the cannabis strains. In some embodiments of the present disclosure, the dominant cannabinoids form at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, or at least about 98% by weight of the total amount of cannabinoids in said cannabis strain. Non-limiting examples of dominant cannabinoids may include: tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), or a combination thereof.

[0126] As used herein the term “non-dominant cannabinoids” refer to cannabinoids that are present at lower concentrations in the cannabis strain. In some embodiments of the present disclosure, the content of said non-dominant cannabinoids in said modified cannabinoid composition is present from at most about 40%, at most about 30%, at most about 20%, at most about 10%, at most about 5%, or at most about 2% by weight of the total amount of cannabinoids in said cannabis strain. Non-limiting examples of dominant cannabinoids may include: cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), cannabielsoin (CBE), cannabicyclol (CBL), cannabicitran (CBT), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), A9-Tetrahydrocannabiphorol (A9-THCP), D9- Tetrahydrocannabutol (A9-THCB), A8-Tetrahydrocannabinol (A8-THC), A6a,10a-Tetrahydrocannabinol (A6a,10a-THC), A8-Tetrahydrocannabivarin (A8-THCV) or a combination thereof.

[0127] In some embodiments of the present disclosure, the method of formulating a modified cannabinoid composition, wherein the enhanced user experience comprises increased organoleptic effects, decreased organoleptic effects, increased physiological effects, decreased physiological effects, increased psychoactive effects, decreased psychoactive effects, or a combination thereof. Preferably, the enhanced user experience involves extended duration, shortened onset time, reduced background effects of terpenes or a combination thereof.

[0128] In another aspect, the present disclosure also encompasses a modified cannabinoid composition formulated according to the method as defined herein above. The modified composition having an enhanced user experience as comparable to the known user experience profile associated with the cannabis strain. Preferably, the determination of the enhanced user experience is performed by trained panelists.

Cannabinoid Composition comprising Modified Cannabinoid Profile

[0129] In accordance with the foregoing, the present disclosure also relates to a cannabinoid composition comprising a modified cannabinoid profile, wherein the modified cannabinoid profile comprises dominant cannabinoids and non-dominant cannabinoids present in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification. Preferably, said cannabinoid composition has been determined to have such property through at least one of the methods disclosed according to the present disclosure.

[0130] Thus, in one aspect, the present disclosure relates to a cannabinoid composition comprising a modified cannabinoid profile, wherein the dominant cannabinoids and non-dominant cannabinoids comprise a subset of cannabinoids having increased influence over the enhanced user experience as comparable to the reference cannabinoid composition without the modification. Preferably, the subset of the dominant and non-dominant cannabinoids having increased influence over the enhanced user experience are different as comparable to a subset of the dominant and the non-dominant cannabinoids that represent the combined highest concentration in the modified cannabinoid profile. The differences between the subsets of cannabinoids could be the different levels of the cannabinoids, different types of the cannabinoids or both.

[0131] In some embodiments of the present disclosure, the subset of the dominant and non-dominant cannabinoids comprises at least 1 or more, at least 2 or more, or at least 3 or more cannabinoids that are different as comparable to the reference cannabinoid composition without the modification. As used herein the expression “enhanced user experience” may refer to characteristics such as improved psychoactive effects, decreased side effects or symptoms or both as comparable to the reference cannabinoid composition without the modification. [0132] Preferably, the improved psychoactive effects may comprise improved psychoactive intensity, longevity, character or a combination thereof, as comparable to the reference cannabinoid composition without the modification. For example, when consumed, the positive effects of the cannabinoid compositions that are reported may include a feeling of euphoria, a sense of relaxation, an energetic feeling or a combination thereof.

[0133] Preferably, the decreased side effects or symptoms may be selected from the group consisting of dysphoria, anxiety, panic, impairment of memory, reductions in psychomotor and cognitive performance, disordered perception of the passage of time, schizophrenic psychosis, tiredness, dizziness, tachycardia, orthostatic hypotension, dry mouth, reduced lacrimation, muscle relaxation, increased appetite, potential irreversible cognitive impairment and a combination thereof.

[0134] In some embodiments of the present disclosure, the cannabinoid composition comprises dominant cannabinoids that are selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and a combination thereof. The dominant cannabinoids may be natural or synthetic analogues thereof, and/or derivatives thereof. In some embodiments of the present disclosure, the dominant cannabinoids are present at relatively lower levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with dominant cannabinoids present in a cannabinoid profile associated with the reference cannabinoid composition without the modification.

[0135] In some embodiments of the present disclosure, the cannabinoid composition comprises non dominant cannabinoids that are selected from the group consisting of cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), cannabielsoin (CBE), cannabicyclol (CBL), cannabicitran (CBT), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), D9- Tetrahydrocannabiphorol (A9-THCP), A9-Tetrahydrocannabutol (A9-THCB), A8-Tetrahydrocannabinol (A8-THC), A6a.1 Oa-Tetrahydrocannabinol (A6a. lOa-THC). A8-Tetrahydrocannabivarin (A8-THCV) and a combination thereof. The non-dominant cannabinoids may be natural or synthetic analogues thereof, and/or derivatives thereof. In some embodiments of the present disclosure, the non-dominant cannabinoids are present at relatively higher levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a cannabinoid profile associated with the reference cannabinoid composition without the modification. [0136] In specific embodiments of the present disclosure, the subset of the dominant cannabinoids and the non-dominant cannabinoids associated with the cannabinoid composition is different as comparable with a subset of dominant cannabinoids and non-dominant cannabinoids associated with the reference cannabinoid composition without the modification.

[0137] The cannabinoid composition of the present disclosure may further comprise at least one terpene. In particular, the at least one terpene is present in an amount of from about 1 wt% to about 30 wt%, preferably from about 3 wt% to about 20 wt%, or preferably from about 5 wt% to about 15 wt%. Non limiting examples of the at least one terpene includes pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, bomeol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, beta-amyrin, thujone, citronellol, pulegone, 1,8-cineole and cycloartenol, or amixture thereof. Other suitable terpenes known to those skilled in the art can also be readily used. Preferably, the cannabinoid composition of the present disclosure possesses a ratio of the terpene(s) to the cannabinoids in the composition of from about 0.1 to about 1.0.

Cannabinoid Composition comprising Modified Terpene Profile

[0138] In another aspect, the present disclosure also relates to a cannabinoid composition comprising a modified terpene profile, wherein the modified terpene profile comprises dominant terpenes and non dominant terpenes present in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification. Preferably, said cannabinoid composition has been determined to have such property through at least one of the methods disclosed according to the present disclosure.

[0139] Thus, the present disclosure relates to a cannabinoid composition comprising a modified terpene profile, wherein the dominant terpenes and the non-dominant terpenes comprises a subset of terpenes having increased influence over the enhanced user experience as comparable to a reference cannabinoid composition without the modification. Preferably, the subset of the dominant and non-dominant terpenes having increased influence over the enhanced user experience are different as comparable to a subset of the dominant and non-dominant terpenes that represent the combined highest concentration in the modified terpene profile. In some embodiments of the present disclosure, the dominant terpenes and the non dominant terpenes comprise a subset of at least 5, at least 7, or at least 10 terpenes having increased influence over the enhanced user experience as comparable to a reference cannabinoid composition without the modification. [0140] In some embodiments of the present disclosure, the cannabinoid composition comprises a subset of the dominant terpenes and non-dominant terpenes having increased influence over the enhanced user experience, wherein the composition comprises at least 1, at least 2 or at least 3 additional non-dominant terpenes.

[0141] In some embodiments of the present disclosure, the expression “enhanced user experience” may refer to characteristics such as improved organoleptic effects, and/or improved physiological effects. Preferably the improvements relate to extended duration time, shortened onset time, reduced background effects of the terpenes or a combination thereof, as comparable to a reference cannabinoid composition without the modification. Preferably, the extended duration time of said improved organoleptic effects and/or physiological effects is characterized by at least about 20% or longer, at least about 30% or longer, or at least about 40% or longer than that of the reference cannabinoid composition without the modification. Preferably, the shortened onset time of said improved organoleptic effects and/or physiological effects is at least about 20% or shorter, at least about 30% or shorter, or at least about 40% or shorter than that of the reference cannabinoid composition without the modification.

[0142] In some embodiments of the present disclosure, the expression “enhanced user experience” may refer to characteristics such as improved aroma or flavor effects. Preferably, the improvements relate to improved aroma or flavor intensity, longevity, character or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

[0143] In some embodiments of the present disclosure, the expression “enhanced user experience” may refer to reduced odor, preferably odorless, as it pertains to the negative or undesirable odor associated with the cannabinoid composition, as comparable to the reference cannabinoid composition without the modification.

[0144] In some embodiments of the present disclosure, the expression “enhanced user experience” may refer to improved attentiveness, mood, cheerfulness, relaxation, vigor, calmness, alertness or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

[0145] In some embodiments, the cannabinoid composition of the present disclosure comprises dominant terpenes, wherein the dominant terpenes are present at relatively lower levels as a percentage of the total terpenes in the modified terpene profile associated with the cannabinoid composition, as comparable with dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification. Preferably, the dominant terpenes are present at about 95% or less, about 90% or less, about 85% or less, or about 80% or less relative to the total terpenes of the modified terpene profile associated with the cannabinoid composition.

[0146] In some embodiments, the cannabinoid composition of the present disclosure comprises non dominant terpenes, wherein the non-dominant terpenes are present at relatively higher levels as a percent of the total terpenes in the modified terpene profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification. Preferably, the non-dominant terpenes are present at about 5% or greater, about 10% or greater, about 15% or greater, or about 20% or greater relative to the total terpenes of the modified terpene profile associated with the cannabinoid composition.

[0147] In some embodiments, the cannabinoid composition of the present disclosure comprises a subset of the dominant terpenes and the non-dominant terpenes, wherein the dominant terpenes and the non dominant terpenes associated with the cannabinoid composition are different as comparable with a subset of dominant terpenes and non-dominant terpenes associated with the reference cannabinoid composition without the modification.

[0148] In some embodiments, the cannabinoid composition of the present disclosure comprises a subset of cannabinoids having increased influence over the enhanced user experience as comparable with a subset of dominant and non-dominant terpenes associated with the reference cannabinoid composition without the modification. Preferably, the subset of the dominant terpenes and the non-dominant terpenes comprises at least 1 or more, at least 2 or more, or at least 3 or more terpenes that are different as comparable to the reference cannabinoid composition without the modification.

[0149] The cannabinoid composition of the present disclosure may further comprise at least one cannabinoid. In particular, the at least one cannabinoid is present in an amount of from about 0.001 mg/mL to about 10 g/mL. Preferably, the at least one cannabinoid is cannabidiol (CBD), tetrahydrocannabinol (THC) or a mixture thereof. In some embodiments of the present disclosure, the at least one cannabinoid is a mixture of THC and CBD in the (w/w) ratio of between about 1:1000 to about 1000:1. In other embodiments of the present disclosure, the cannabinoid is an isolated cannabinoid having > 90%, > 95%, > 98%, > 99% or > 99.5% purity present in at least one carrier oil. As used herein, the term “carrier oil” means an oil suitable for human and/or animal consumption. Carrier oils can be hydrogenated oils, chemically or enzymatically interesterified oils, fractionated oils, and blended oils. Suitable non-limiting examples may include: a medium chain triglyceride (e.g., Labrafac™ CC MCT), a coconut oil, a citrus oil (e.g., lemon oil, orange oil), a com oil, a cottonseed oil, a flax seed oil, a grape seed oil, a marine oil ( e.g ., a fish oil, an algal oil, a fungal oil), a mustard oil, a nut oil (e g., almond oil, cashew oil, walnut oil), an olive oil, a palm oil (and fractions), a peanut oil, a rapeseed oil (e.g. , a canola oil), a rice bran oil, a safflower oil, a sesame oil, a soybean oil, a sunflower oil, or mixtures thereof. The carrier oil can be used either singly or in combination with one another.

Cannabinoid Composition comprising Modified Terpene Profile and Modified Cannabinoid Profile

[0150] In another aspect, the present disclosure also relates to a cannabinoid composition comprising a modified terpene profile comprising dominant terpenes and non-dominant terpenes and a modified cannabinoid profile comprising dominant cannabinoids and non-dominant cannabinoids. The terpenes and the cannabinoids are present in the cannabinoid composition in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification.

[0151] Thus, the present disclosure relates to a cannabinoid composition comprising a modified terpene profile wherein the dominant terpenes and non-dominant terpenes comprise a subset of terpenes having increased influence over the enhanced user experience as comparable to a reference cannabinoid composition without the modification. Preferably, the subset of the dominant terpenes and non-dominant terpenes having the increased influence over the enhanced user experience are different as comparable to a subset of the dominant and non-dominant terpenes that represent the combined highest concentration in the modified terpene profile. In some embodiments of the present disclosure, the dominant terpenes and the non-dominant terpenes comprise a subset of at least 5, at least 7, or at least 10 terpenes having increased influence over the enhanced user experience as comparable to a reference cannabinoid composition without the modification.

[0152] In some embodiments of the present disclosure, the cannabinoid composition comprises a subset of the dominant and non-dominant terpenes having the increased influence over the enhanced user experience, wherein the composition comprises at least 1, at least 2 or at least 3 additional non-dominant terpenes.

[0153] In some embodiments of the present disclosure, the expression “enhanced user experience” may refer to characteristics such as improved organoleptic effects, and/or improved physiological effects. Preferably the improvements relate to extended duration time, shortened onset time, reduced background effects of the terpenes or a combination thereof, as comparable to a reference cannabinoid composition without the modification. [0154] In some embodiments of the present disclosure, the expression “enhanced user experience” may refer to characteristics such as improved aroma or flavor effects. Preferably, the improvements relate to improved aroma or flavor intensity, longevity, character or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

[0155] In some embodiments of the present disclosure, the expression “enhanced user experience” may refer to reduced odor, preferably odorless, as it pertains to the negative or undesirable odor associated with the cannabinoid composition, as comparable to the reference cannabinoid composition without the modification.

[0156] In some embodiments of the present disclosure, the expression “enhanced user experience” may refer to improved attentiveness, mood, cheerfulness, relaxation, vigor, calmness, alertness or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

[0157] In some embodiments, the cannabinoid composition of the present disclosure comprises dominant terpenes, wherein the dominant terpenes are present at relatively lower levels as a percentage of the total terpenes in the modified terpene profile associated with the cannabinoid composition, as comparable with dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification.

[0158] In some embodiments, the cannabinoid composition of the present disclosure comprises non dominant terpenes, wherein the non-dominant terpenes are present at relatively higher levels as a percent of the total terpenes in the modified terpene profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification. Preferably, the dominant terpenes are present at about 95% or less, about 90% or less, about 85% or less, or about 80% or less relative to the total terpenes of the modified terpene profile associated with the cannabinoid composition.

[0159] In some embodiments, the cannabinoid composition of the present disclosure comprises non dominant terpenes, wherein the non-dominant terpenes are present at relatively higher levels as a percent of the total terpenes in the modified terpene profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification. Preferably, the non-dominant terpenes are present at about 5% or greater, about 10% or greater, about 15% or greater, or about 20% or greater relative to the total terpenes of the modified terpene profile associated with the cannabinoid composition. [0160] In some embodiments of the present disclosure, the subset of the dominant terpenes and the non dominant terpenes associated with the cannabinoid composition is different as comparable with a subset of dominant terpenes and non-dominant terpenes associated with the reference cannabinoid composition without the modification. Preferably, the subset of the dominant terpenes and non-dominant terpenes comprises at least 1 or more, at least 2 or more, or at least 3 or more terpenes that are different as comparable to the reference cannabinoid composition without the modification.

[0161] In some embodiments of the present disclosure, the cannabinoid composition comprises dominant cannabinoids and non-dominant cannabinoids. The dominant and non-dominant cannabinoids comprises a subset of cannabinoids having increased influence over the enhanced user experience as comparable to the reference cannabinoid composition without the modification. Preferably, the subset of the dominant cannabinoids and non-dominant cannabinoids having increased influence over the enhanced user experience are different as comparable to a subset of the dominant cannabinoids and the non-dominant cannabinoids that represent the highest concentration in the modified cannabinoid profile. The differences between the subsets of cannabinoids could be the different levels of the cannabinoids, different types of the cannabinoids or both.

[0162] In some embodiments, the present disclosure also relates to a cannabinoid composition comprising a subset of dominant cannabinoids and non-dominant cannabinoids. Preferably, the subset of the dominant cannabinoids and non-dominant cannabinoids comprises at least 1 or more, at least 2 or more, or at least 3 or more cannabinoids that are different as comparable to the reference cannabinoid composition without the modification. As used herein the expression “enhanced user experience” may refer to characteristics such as improved psychoactive effects, decreased side effects or symptoms or both as comparable to the reference cannabinoid composition without the modification.

[0163] Preferably, the improved psychoactive effects may comprise improved psychoactive intensity, longevity, character or a combination thereof, as comparable to the reference cannabinoid composition without the modification. For example, when consumed, the positive effects of the cannabinoid compositions that are reported may include a feeling of euphoria, a sense of relaxation, an energetic feeling or a combination thereof.

[0164] Preferably, the decreased side effects or symptoms may be selected from the group consisting of dysphoria, anxiety, panic, impairment of memory, reductions in psychomotor and cognitive performance, disordered perception of the passage of time, schizophrenic psychosis, tiredness, dizziness, tachycardia, orthostatic hypotension, dry mouth, reduced lacrimation, muscle relaxation, increased appetite, potential irreversible cognitive impairment and a combination thereof.

[0165] In some embodiments of the present disclosure, the cannabinoid composition comprises dominant cannabinoids that are selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and a combination thereof. The dominant cannabinoids may be natural or synthetic analogues thereof, and/or derivatives thereof. In some embodiments of the present disclosure, the dominant cannabinoids are present at relatively lower levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with dominant cannabinoids present in a cannabinoid profile associated with the reference cannabinoid composition without the modification. In some embodiments of the present disclosure, the non-dominant cannabinoids are present at relatively higher levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a cannabinoid profile associated with the reference cannabinoid composition without the modification.

[0166] In some embodiments of the present disclosure, the cannabinoid composition comprises non dominant cannabinoids that are selected from the group consisting of cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), cannabielsoin (CBE), cannabicyclol (CBL), cannabicitran (CBT), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), D9- Tetrahydrocannabiphorol (A9-THCP), A9-Tctrahydrocannabutol (A9-THCB), A8-Tctrahydrocannabinol (A8-THC), A6a.1 Oa-Tctrahydrocannabinol (A6a. lOa-THC). A8-Tctrahydrocannabi\ arin (A8-THCV) and a combination thereof. The non-dominant cannabinoids may be natural or synthetic analogues thereof, and/or derivatives thereof. In some embodiments of the present disclosure, the non-dominant cannabinoids are present at relatively higher levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a cannabinoid profile associated with the reference cannabinoid composition without the modification.

Method of Formulating a Cannabinoid Composition

[0167] In one aspect, the present disclosure provides a method of formulating a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified cannabinoid profile as defined herein; and b) selecting dominant cannabinoids and non-dominant cannabinoids based on the modified cannabinoid profile. Preferably, the selection is based on the modified cannabinoid profile’s influence on the enhanced user experience.

[0168] In another aspect, the present invention disclosure provides a method of formulating a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified terpene profile as defined herein; and b) selecting dominant terpenes and non-dominant terpenes based on the modified terpene profile. Preferably, the selection is based on the modified terpene profile’s influence on the enhanced user experience.

[0169] In yet another aspect, the present disclosure also provides a method of formulating a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified cannabinoid profile and a modified terpene profile as defined herein; b) selecting dominant cannabinoids and non-dominant cannabinoids based on the modified cannabinoid profile; and c) selecting dominant terpenes and non dominant terpenes based on the modified terpene profile. Preferably, the selection is based on the modified cannabinoid profile’s and the modified terpene profile’s influence on the enhanced user experience.

Cannabinoid Product

[0170] In an additional aspect, the present invention also relates to a cannabinoid product comprising the cannabinoid composition as defined herein. The cannabinoid composition is formed into a cannabinoid product whereby it has been mixed, infused or incorporated in the cannabinoid product comprising at least 1 mg, at least 5 mg or at least 10 mg per product package. The term “cannabinoid product” refers to a liquid beverage, a human edible product, a pet edible product or an inhalant product. The cannabinoid product may contain additional ingredients such as, for example, flavorants, aromatics or both.

[0171] As used herein, the term “liquid beverage” means water, juice or dairy based liquid beverage product. For non-limiting examples, the liquid beverage is selected from the group consisting of carbonated drink, nitrogenated drink, natural fruit juice, synthetic fruit juice, natural vegetable juice, synthetic vegetable juice, distilled water, alkaline water, purified water, mineral water, coconut water, sparkling water, flavored water, coffee, tea, herbal tea, energy drink, non-alcoholic beverage, alcoholic beverage, tincture and cola beverage.

[0172] In some embodiments, the liquid beverage product is selected from the group consisting of drinking water, juice, coffee, caffeinated beverage, tea, herbal tea, energy drink, non-alcoholic beverage (e.g., non alcoholic beer), alcoholic beverage, tincture and cola beverage. [0173] The liquid beverage product is preferably selected from the group consisting of distilled water, alkaline water, purified water, mineral water, coconut water, sparkling water, and flavored water. The liquid beverage product may also be selected from the group consisting of natural fruit juice, synthetic fruit juice, natural vegetable juice, and synthetic vegetable juice. In some embodiments, the liquid beverage product is a carbonated drink or a nitrogenated drink. In some embodiments, the liquid beverage product is an alcoholic beverage, preferably the alcoholic beverage is selected from the group consisting of beer, distilled spirit, lager, cider, wine/fortified wine and cocktail. Preferably the liquid beverage is tincture. In some embodiments, the liquid beverage product is substantially free or free of alcohol.

[0174] The liquid beverage may contain other ingredients such as, for non-limiting example, preservatives, flavorants, sweeteners, stabilizers, dyes, or carbonation. Preferably, the beverage base is a cannabinoid- less beverage before the introduction of the cannabinoid composition of the present disclosure.

[0175] In one aspect, a key to consumer acceptability of such a liquid beverage product is clear physical appearance (for clear beverages), no discoloration (for opaque beverages) and/or no adverse visual effects (e.g., ringing, creaming, etc.) across the beverage as it is consumed. It is well known that cannabinoids in aqueous solution can cause precipitation, ringing and/or creaming effects. This issue may also be magnified when the liquid beverage product comprises elevated amounts of the cannabinoids. As a result, consumers may not want to consume liquid beverage products that precipitate or become cloudy when stored or kept available for extended periods. Accordingly, in some embodiments, the liquid beverage product has a turbidity of about 30 Nephelometric Turbidity Units (NTU) or less, preferably about 25 NTU or less, or preferably about 20 NTU or less, preferably after a storage period of at least 2 weeks, preferably after at least 1 month, or preferably after at least 2 months at 40°C.

[0176] In some embodiments, the liquid beverage product does not contain visible particles, does not contain visible crystals, does not exhibit phase separation, and/or does not exhibit ringing or is at least about as clear as the cannabinoid-less beverage or the beverage base in the absence of the liquid cannabinoid concentrate composition, preferably after a storage period of at least 2 weeks, preferably after at least 1 month, or preferably after at least 2 months at 40°C. Preferably, the liquid beverage product of the present disclosure has a viscosity in the range of from about 50 mPa· s to 1500 mPa· s.

[0177] In some embodiments, the cannabinoid composition is formed into an edible product intended for human consumption. A human edible product can be any product that is suitable, e.g., non-toxic, for placing into the mouth of a human, whether ingested, absorbed, or only chewed or sucked on and at least a portion discarded, etc. Preferably, the human edible product does not have a perceptible cannabis odor to a subject consuming the edible. Illustrative examples of human edible products include chewing or bubble gums, mints, suckers, jawbreakers, lozenges, hard candies, gummy candies, taffies, chocolates, brownies, cookies, crackers, granola or meal replacement bars, smokeless inhalation powders, honey, syrup, spreads, and dissolving strips. Preferably, the human edible products include gums, hard candies, soft candies, gummy candies, jellies, or lozenges, more preferably chewing or bubble gum or mints.

[0178] The amount of the cannabinoids in a human edible product may be enough to produce noticeable psychoactive effects associated with cannabinoids in a subject consuming at least a recommended amount of the edible product. Generally, a recommended amount is an amount that will produce psychoactive effects but not so great as to cause undesirable side effects or toxic effects.

[0179] The amount of the cannabinoids in a human edible product may be enough to produce a therapeutic and/or prophylactic effect associated with cannabinoids in a subject consuming at least a recommended amount of the edible product. For example, a recommended amount is an amount that will produce reduction in the feeling of anxiety.

[0180] In some embodiments, the cannabinoid composition is formed into an edible product intended for animal consumption. Preferably, the cannabinoid composition of the present disclosure is formed into an edible pet product, preferably an edible pet food or an edible pet chew.

[0181] In some embodiments, the cannabinoid composition is formed into an inhalant product, preferably a vaporizer inhalant, or even more preferably a recreational vaporizer inhalant. The inhalant product can be in any form appropriate for human consumption, including a liquid, an oil, an emulsion, a gel, an aerosol or a solid. Preferred examples of the recreational vaporizer inhalant are selected from the group consisting of oils or liquids for electronic cigarettes, vape, hookah products and incense.

[0182] Preferably, the inhalant product is formulated for administration by inhalation. In certain of these embodiments, the inhalant product is formulated for administration by a vaporizer, nebulizer or aerosolizer. In some embodiments, unit dosage forms of the inhalant product described herein are provided that are adapted for administration by inhalation. For example, the unit dosage forms of the inhalant product may be a vial, an ampule, or a pod, optionally scored to allow user opening. Method for Enhancing a User Experience

[0183] In an additional aspect, the present disclosure also relates to a method for enhancing a user experience of a cannabinoid product as defined herein comprising providing the cannabinoid as defined herein. Preferably, the enhanced user experience provides improved psychoactive effects, decreased side effects or symptoms or both as comparable to a reference cannabinoid product without the modified cannabinoid profile. Preferably, in the method of the present disclosure the enhancement of the user experience occurs during combustion and inhalation of the cannabinoid product.

[0184] In specific embodiments thereof, the improved psychoactive effects comprise improved psychoactive intensity, longevity, character or a combination thereof.

[0185] In other specific embodiments thereof, the decreased side effects or symptoms comprise decreased dysphoria, anxiety, panic, impairment of memory, reductions in psychomotor and cognitive performance, disordered perception of the passage of time, schizophrenic psychosis, tiredness, dizziness, tachycardia, orthostatic hypotension, dry mouth, reduced lacrimation, muscle relaxation, increased appetite, potential irreversible cognitive impairments or a combination thereof.

[0186] In yet other specific embodiments thereof, the enhanced user experience provides improved organoleptic effects and/or improved physiological effects as comparable to a reference cannabinoid product without the modified terpene profile. Suitable non-limiting examples of the improved organoleptic effects are selected from the group consisting of improved aroma, improved flavor, reduced odor, and a combination thereof. Suitable non-limiting examples of the improved physiological effects are selected from the group consisting of attentiveness, mood (e.g., cheerfulness), relaxation, vigor, calmness, alertness and a combination thereof.

EXAMPLE

[0187] The following examples are provided to further illustrate the present disclosure and are not to be construed as limitations of the present disclosure, as many variations of the present disclosure are possible without departing from its spirit or scope.

Example 1 - Selecting a Cannabis Strain

[0188] The cannabis strain selected is Pineapple Express (available from Fully’s Wildflowers). This cannabis strain is known to have a unique user experience profile characterized by the effects on the mind and body, and its refreshing aroma and flavor. In particular, the aroma of this cannabis strain is characterized as having overtones of fresh cut pineapple and mango, and undertones of fresh apple and pine. The flavor of this cannabis strain is characterized as tasting of pineapple, pine and cedar. Pineapple Express is known to provide a long lasting energetic effect whereby the user typically experiences feelings of being uplifted, euphoria and happiness. It has also been known to cause head happy high that leaves user feeling creative and talkative, and causes the body to relax (see for example https://www.leafly.com/strains/pineapple-express). Together these attributes comprises the “known user experience profile” associated with this cannabis strain.

Example 2 - Descriptive Analysis Measurements of the Cannabis Strain

[0189] Descriptive analysis method used to identified and quantified the sensorial attributes of a cannabis strain involves the use of human subjects who have been specifically chosen and trained for this purpose (i.e., trained panelists). The samples of the cannabis strain are evaluated by 10 trained panelists per session.

[0190] The cannabis strain is obtained as either dried flower or a liquid oil concentrate cartridge. If the cannabis strain is a dried flower, then it needs to be grounded first before being placed into a vaporizer device (e.g., Pax 2 vaporizer). Liquid oil concentrate cartridges can be simply snapped into place with a vaporizer device (e.g., RUBI from KandyPens).

(i) Aroma Profile

[0191] The samples are assessed for the aroma profile at 3-5 seconds after the vaping incident (i.e., taking a puff). The trained panelists are asked to repeat the assessment for 5 vaping incidents and placed their noses within 2-5 cm from the source of the aroma. The trained panelists are asked to score the “character” and “intensity” of the aroma profile. The “character” of the aroma is scored using the aroma descriptors provided in Table 2 and the “intensity” of the aroma is scored on a scale of 0 to 15, with 0 being “none” and 15 being “very strong”. The results (data not shown) are collected and analyzed using analysis of variance (ANOVA) to determine the aroma profile, which is statistically significant.

(iil Flavor Profile

[0192] The samples are also assessed for taste at 3-5 seconds after the vaping incident to determine the flavor profile. The trained panelists are asked to repeat the assessment for 5 vaping incidents. The “character” of the flavor is scored using the flavor descriptors provided in Table 3 and the “intensity” of the flavor is scored on a scale of 0 to 15, with 0 being “none” and 15 being “very strong”. The results (data not shown) are collected and analyzed using analysis of variance (ANOVA) to determine the flavor profile, which is statistically significant.

Example 3 - Analytical Analysis of the Cannabis Strain

[0193] The terpenes present in the cannabis sample can be purified, analyzed and identified, by any one of methodologies such as for example, high pressure liquid chromatography (HPLC), gas chromatography and other chromatographic techniques known in the art and/or described herein above. The levels of the dominant terpenes present in this cannabis strain are shown in Table 6.

Table 6 - Dominant Terpenes in Pineapple Express

*Available from archive.analytical360.com

Example 4 - Correlation of the Results of the Descriptive Analysis (DAI to the Results of the Analytical Analysis of the Cannabis Strain to Determine the Quantified User Experience Profile

[0194] Using the results of the Analytical Analysis of the cannabis strain, it is possible to attribute the effects of each component of the terpene profile to the average aroma profile, and average flavor profile. The average aroma profile, and average flavor profile are calculated from the replicates on the test samples with multiple trained panelists.

[0195] It is useful to consider the difference (D) in each of the average aroma profile, and average flavor profile between the terpene profile. This method allows one to determine the relative effect of each terpene on the average aroma profile, and average flavor profile. The difference (D) can then be plotted (data not shown) for each of the average aroma profile, and average flavor profile to generate the quantified user experience profile associated with the sampled cannabis strain.

(i) Quantified Aroma Profile

[0196] The average aroma profile has intense pineapple, fresh apple and mango overtones (i.e., aroma intensity rating of > 10) and minor pine undertones (i.e., aroma intensity rating of < 7). As noted in Table 6 above, the dominant terpenes based on the Analytical Analysis include: Humulene, Myrcene and Caryophyllene. Humulene is what gives this cannabis strain its distinct “hoppy” aroma. The aroma for Myrcene has been described as musky, earthy and herbal. Caryophyllene, particularly b-Caryophyllene, has an aroma characterized as peppery, woody, spicy and hoppy. It appears that the dominant terpenes do not readily reflect the aroma profile actually experienced by the trained panelists. In addition to the dominant terpenes, the cannabis strains also include non-dominant terpenes such as, for example, Linalool, Limonene, and Bisabolol. Limonene provides a citrusy aroma and the more common d-isomer smells like oranges. Linalool has a candy-like aroma. Bisabolol also provides a floral aroma. Therefore, the quantified terpene profile associated with the quantified user experience profile has increased levels of the non dominant terpenes Linalool, Limonene, and Bisabolol versus the existing dominant terpenes. The resultant quantified terpene profile has the desired effect of providing an aroma profile that more accurately reflects the actual user experience.

(ii) Quantified Flavor Profile

[0197] The average flavor profile has an intense tropical pineapple taste (i.e., flavor intensity rating of > 10) and minor pine taste as well (i.e., flavor intensity rating of < 7). As noted in Table 6 above, the dominant terpenes based on the Analytical Analysis include: Humulene, Myrcene and Caryophyllene. Myrcene provides the citrus and tropical fruit flavors. Linalool, which is a non-dominant terpene, offers an earthy pine flavor. Thus, it is desirable to increase the relative levels of the Myrcene and the Linalool to enhance these sweet, tropical and piney flavors. The resultant quantified terpene profile has the desired effect of providing a flavor profile that more accurately reflects the actual user experience.

[0198] The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a dimension disclosed as “40 mm” is intended to mean “about 40 mm”. [0199] Every document cited herein, including any cross referenced or related patent or application and any patent application or patent to which this application claims priority or benefit thereof, is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to any disclosure disclosed or claimed herein or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses any such disclosure. Further, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.

[0200] While particular embodiments of the present disclosure have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the scope of the present disclosure. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this disclosure.

Claims

CLAIMS What is claimed is:

1. A method of quantifying a user experience associated with a cannabis strain comprising: a) selecting a cannabis strain having a known user experience profde; b) determining one or more user experience characteristics of the cannabis strain as measured by descriptive analysis (DA); c) assessing the presence and levels of cannabinoids and/or terpenes from the cannabis strain by analytical analysis (AA); and d) correlating the presence and levels of the cannabinoids and/or terpenes from the analytical analysis (AA) to results of the descriptive analysis (DA) to generate a quantified user experience profile associated with the cannabis strain.

2. The method according to claim 1, wherein, d) the quantified user experience profile comprises a terpene profile and/or a cannabinoid profile, wherein

(i) the correlation of the presence and levels of the cannabinoids from the analytical analysis (AA) to the results of the cannabinoids from the descriptive analysis (DA) generates the cannabinoid profile, and/or

(ii) the correlation of the presence and levels of the terpenes from the analytical analysis (AA) to the results of the terpenes from the descriptive analysis (DA) generates the terpene profile.

3. The method according to claim 1 or 2, further comprising: e) formulating a cannabinoid composition based on the quantified user experience profile.

4. The method according to claim 3, further comprising: f) determining that the cannabinoid composition provides the user experience that is similar, preferably substantially similar, to the known user experience profile of the cannabis strain.

5. The method according to claim 1 or 2, further comprising: e) formulating a modified cannabinoid composition based on the quantified user experience profile.

6. The method according to claim 5, further comprising: f) determining that the modified cannabinoid composition provides an enhanced user experience in comparison to the known user experience profile of the cannabis strain.

7. The method according to any one of claims 1 to 6, wherein the cannabis strain is a natural cannabis strain.

8. The method according to claim 3 or 4, wherein the user experience characteristics are measured by the descriptive analysis (DA) using sensory analysis to evaluate 1 or more descriptors selected from the group consisting of an organoleptic effect, a physiological effect, and a psychoactive effect.

9. The method according to claim 5 or 6, wherein the user experience characteristics are measured by the descriptive analysis (DA) using sensory analysis to evaluate 1 or more descriptors selected from the group consisting of an organoleptic effect, a physiological effect, and a psychoactive effect.

10. The method according to claim 8, wherein the sensory analysis involves at least 2 or more descriptors, or preferably all 3 descriptors.

11. The method according to claim 8, wherein the organoleptic effect is an aroma having an aroma intensity rating attributable to the cannabis strain as assessed by the descriptive analysis (DA).

12. The method according to claim 9, wherein the sensory analysis involves at least 2 or more descriptors, or preferably all 3 descriptors.

13. The method according to claim 9, wherein the organoleptic effect is an aroma having an aroma intensity rating attributable to the cannabis strain as assessed by the descriptive analysis (DA).

14. The method according to claim 13, wherein the modified cannabinoid composition is characterized by the aroma intensity rating that is at least about 10% or greater, at least about 20% or greater, or at least about 30% or greater as compared with that of an aroma intensity rating of an unmodified cannabinoid composition.

15. The method according to claim 8, wherein the organoleptic effect is a flavor having a flavor impression rating attributable to the cannabis strain as assessed by the descriptive analysis (DA).

16. The method according to claim 9, wherein the organoleptic effect is a flavor having a flavor impression rating attributable to the cannabis strain as assessed by the descriptive analysis (DA).

17. The method according to claim 16, wherein the modified cannabinoid composition is characterized by the flavor impression rating that is at least about 10% greater, at least about 20% greater, or at least about 30% or greater as compared with that of a flavor impression rating of an unmodified cannabinoid composition.

18. The method according to claim 8, wherein the physiological effect has a physiological effect intensity rating attributable to the cannabis strain as assessed by the descriptive analysis (DA).

19. The method according to claim 9, wherein the physiological effect has a physiological effect intensity rating attributable to the cannabis strain as assessed by the descriptive analysis (DA).

20. The method according to claim 19, wherein the modified cannabinoid composition is characterized by the physiological effect intensity rating that is at least 10% or greater, at least 20% or greater, or at least 30% or greater as compared with that of a physiological effect intensity rating of an unmodified cannabinoid composition.

21. The method according to claim 8, wherein the psychoactive effect has a psychoactive effect intensity rating attributable to the cannabis strain as assessed by the descriptive analysis (DA).

22. The method according to claim 9, wherein the psychoactive effect has a psychoactive effect intensity rating attributable to the cannabis strain as assessed by the descriptive analysis (DA).

23. The method according to claim 22, wherein the modified cannabinoid composition is characterized by the psychoactive effect intensity rating that is at least about 10% or greater, at least about 20% or greater, or at least about 30% or greater as compared with that of a psychoactive effect intensity rating of an unmodified cannabinoid composition.

24. The method according to any one of claims 1 to 23, wherein the presence and levels of the cannabinoids and/or the terpenes from the cannabis strain are assessed by chromatography, preferably gas chromatography or high performance liquid chromatography (HPLC).

25. The method according to claim 24, wherein the presence and levels of the cannabinoids and/or the terpenes from the cannabis strains are assessed by gas chromatography olfactometry-mass spectrometry (GCO-MS), gas chromatography flame ionization detector (GC-FID) or high performance liquid chromatography-mass spectrometry (HPLC-MS).

26. The method according to claim 2, wherein step d) involves correlating the assessed presence and levels of the terpenes from the analytical analysis (AA) with the results of the descriptive analysis (DA), preferably of an aroma, a flavor or a combination thereof, to provide a terpene profile.

27. The method according to claim 2, wherein step d) involves correlating the measured presence and levels of the cannabinoids from the analytical analysis (AA) with the results of the descriptive analysis (DA), preferably of a physiological effect, a psychoactive effect or a combination thereof, to provide a cannabinoid profile.

28. A system comprising: a) an input of one or more user experience characteristics of a cannabis strain as measured by descriptive analysis (DA) from one or more subjects, wherein each of the user experience characteristic is generated based on at least one or more of: (i) an organoleptic effect, (ii) a physiological effect, or (iii) a psychoactive effect; b) a chemical analyzer configured to:

(i) receive a cannabis strain having a known user experience profile, the cannabis strain comprising one or more terpenes and/or one or more cannabinoids; and

(ii) chemically analyze the cannabis strain to determine the presence and levels of the one or more terpenes and/or cannabinoids; and c) a computer-implemented correlator for correlating the presence and levels of the terpenes and/or cannabinoids from the analytical analysis (AA) to results of the descriptive analysis (DA) to generate a quantified user experience profile associated with the cannabis strain.

29. The system according to claim 28, wherein the chemical analyzer includes one or more of gas chromatography olfactometry-mass spectrometry (GCO-MS), gas chromatography flame ionization detector (GC-FID) or high performance liquid chromatography-mass spectrometry (HPLC-MS).

30. The system according to claim 28 or 29, wherein the cannabis strain is a natural cannabis strain.

31. A method for formulating a cannabinoid composition having a user experience profile that is similar, preferably substantially similar, to a known user experience profile of a cannabis strain, the method comprises: a) receiving a quantified user experience profile as defined in any one of claims 1 to 27; b) selecting cannabinoids and/or terpenes based on the quantified user experience profile; and c) forming the cannabinoid composition, wherein the cannabinoid composition comprises the cannabinoids and/or the terpenes at levels similar to cannabinoids and/or terpenes present in the quantified user experience profile.

32. The method according to claim 31, further comprises determining that the cannabinoid composition provides the user experience that is similar, preferably substantially similar, to the known user experience profile of the cannabis strain.

33. A cannabinoid composition formulated according to the method as defined in claim 31 or 32 and having a user experience that is similar, preferably substantially similar, to the known user experience profile associated with the cannabis strain.

34. A method of formulating a modified cannabinoid composition having an enhanced user experience as comparable to a known user experience profile of a cannabis strain, the method comprising: a) receiving a quantified user experience profile as defined in any one of claims 1 to 27; b) selecting cannabinoids and/or terpenes matched to their relative contributions to the desired user experience characteristics of the quantified user experience profile; and c) forming the modified cannabinoid composition, wherein the modified cannabinoid composition comprises subsets of cannabinoids and/or terpenes at levels dissimilar to cannabinoids and/or terpenes present in the quantified user experience profile.

35. The method according to claim 34, further comprising determining that the modified cannabinoid composition provides an enhanced user experience in comparison to the known user experience profile of the cannabis strain.

36. The method according to claim 34 or 35, wherein b) selecting dominant terpenes and non-dominant terpenes matched to their relative contributions to the desired user experience characteristics of the quantified user experience profile.

37. The method according to claim 34 or 35, wherein b) selecting dominant cannabinoids and non-dominant cannabinoids matched to their relative contributions to the desired user experience characteristics of the quantified user experience profile.

38. The method according to any one of claims 34 to 37, wherein the enhanced user experience comprises increased organoleptic effects, decreased organoleptic effects, increased physiological effects, decreased physiological effects, increased psychoactive effects, decreased psychoactive effects, or a combination thereof, preferably the enhanced user experience involves extended duration, shortened onset time, reduced background effects of terpenes or a combination thereof.

39. A cannabinoid composition comprising a modified cannabinoid profile, wherein the modified cannabinoid profile comprises dominant cannabinoids and non-dominant cannabinoids present in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification.

40. The cannabinoid composition according to claim 39, wherein the dominant and non-dominant cannabinoids comprise a subset of cannabinoids having increased influence over the enhanced user experience as comparable to the reference cannabinoid composition without the modification.

41. The cannabinoid composition according to claim 40, wherein the subset of the dominant and non dominant cannabinoids having increased influence over the enhanced user experience are different as comparable to a subset of the dominant and non-dominant cannabinoids that represent the combined highest concentration in the modified cannabinoid profile.

42. The cannabinoid composition according to claim 41, wherein the difference comprises different levels of the cannabinoids, different types of the cannabinoids or both.

43. The cannabinoid composition according to any one of claims 39 to 42, wherein the subset of the dominant and non-dominant cannabinoids comprises at least 1 or more, at least 2 or more, or at least 3 or more cannabinoids that are different as comparable to the reference cannabinoid composition without the modification.

44. The cannabinoid composition according to any one of claims 39 to 43, wherein the enhanced user experience comprises improved psychoactive effects, decreased side effects or symptoms or both as comparable to the reference cannabinoid composition without the modification.

45. The cannabinoid composition according to claim 44, wherein the enhanced user experience comprises improved psychoactive intensity, longevity, character or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

46. The cannabinoid according to claim 45, wherein the improved psychoactive comprises a feeling of euphoria, a sense of relaxation, an energetic feeling, or a combination thereof.

47. The cannabinoid composition according to claim 46, wherein the decreased side effects or symptoms are selected from the group consisting of dysphoria, anxiety, panic, impairment of memory, reductions in psychomotor and cognitive performance, disordered perception of the passage of time, schizophrenic psychosis, tiredness, dizziness, tachycardia, orthostatic hypotension, dry mouth, reduced lacrimation, muscle relaxation, increased appetite, potential irreversible cognitive impairment and a combination thereof.

48. The cannabinoid composition according to any one of claims 39 to 47, wherein the dominant cannabinoids are selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and a combination thereof, preferably natural or synthetic analogues thereof, and/or derivatives thereof.

49. The cannabinoid composition according to any one of claims 39 to 48, wherein the non-dominant cannabinoids are selected from the group consisting of cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), cannabielsoin (CBE), cannabicyclol (CBL), cannabicitran (CBT), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), A9-Tctrahydrocannabiphorol (A9-THCP), A9-Tctrahydrocannabutol (A9-THCB), D8- Tetrahydrocannabinol (A8-THC), A6a.1 Oa-Tctrahydrocannabinol (A6a.1 Oa-THC). D8- Tetrahydrocannabivarin (A8-THCV) and a combination thereof, preferably natural or synthetic analogues thereof, and/or derivatives thereof.

50. The cannabinoid composition according to any one of claims 39 to 49, wherein the dominant cannabinoids are present at relatively lower levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with dominant cannabinoids present in a cannabinoid profile associated with the reference cannabinoid composition without the modification.

51. The cannabinoid composition according to any one of claims 39 to 50, wherein the non-dominant cannabinoids are present at relatively higher levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a cannabinoid profile associated with the reference cannabinoid composition without the modification.

52. The cannabinoid composition according to claim 40 or 41, wherein the subset of the dominant cannabinoids and the non-dominant cannabinoids associated with the cannabinoid composition is different as comparable with a subset of dominant cannabinoids and non-dominant cannabinoids associated with the reference cannabinoid composition without the modification.

53. The cannabinoid composition according to any one of claims 39 to 52 further comprising at least one terpene.

54. The cannabinoid composition according to claim 53, wherein the at least one terpene is present in an amount of from about 1 wt% to about 30 wt%, preferably from about 3 wt% to about 20 wt%, or preferably from about 5 wt% to about 15 wt%.

55. The cannabinoid composition according to claim 54, wherein the at least one terpene is pinene, limonene, linalool, caryophyllene, caryophyllene oxide, myrcene, humulene, bomeol, eucalyptol, terpineol, nerolidol, phytol, geraniol, bisabolol, camphene, beta-amyrin, thujone, citronellol, pulegone, 1,8-cineole and cycloartenol or a mixture thereof.

56. The cannabinoid composition according to any one of claims 53 to 55, wherein a ratio of the terpene(s) to the cannabinoids in the composition is from about 0.1 to about 1.0.

57. A cannabinoid composition comprising a modified terpene profile, wherein the modified terpene profile comprises dominant terpenes and non-dominant terpenes present in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification.

58. The cannabinoid composition according to claim 57, wherein the dominant terpenes and the non dominant terpenes comprise a subset of terpenes having increased influence over the enhanced user experience as comparable to a reference cannabinoid composition without the modification.

59. The cannabinoid composition according to claim 57, wherein the dominant terpenes and non dominant terpenes comprise a subset of at least 5, at least 7, or at least 10 terpenes having increased influence over the enhanced user experience as comparable to a reference cannabinoid composition without the modification.

60. The cannabinoid composition according to claim 58 or 59, wherein the subset of the dominant and non-dominant terpenes having increased influence over the enhanced user experience are different as comparable to a subset of the dominant and non-dominant terpenes that represent the combined highest concentration in the modified terpene profile.

61. The cannabinoid composition according to claim 60, wherein the subset of the dominant and non dominant terpenes having increased influence over the enhanced user experience comprises at least 1, at least 2 or at least 3 additional non-dominant terpenes.

62. The cannabinoid composition according to any one of claims 57 to 61, wherein the enhanced user experience comprises improved organoleptic effects, and/or improved physiological effects, preferably extended duration, shortened onset time, reduced background effects of terpenes or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

63. The cannabinoid composition according to claim 62, wherein the extended duration time of said improved organoleptic effects and/or physiological effects is at least about 20% or longer, at least about 30% or longer, or at least about 40% or longer than that of the reference cannabinoid composition without the modification.

64. The cannabinoid composition according to claim 62, wherein the shortened onset time of said improved organoleptic effects and/or physiological effects is at least 20%, at least 30% or at least 40% shorter than that of the reference cannabinoid composition without the modification.

65. The cannabinoid composition according to claim 62, wherein the enhanced user experience comprises improved aroma or flavor effects, preferably improved aroma or flavor intensity, longevity, character or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

66. The cannabinoid composition according to claim 62, wherein the enhanced user experience comprises reduced odor, preferably odorless, as comparable to the reference cannabinoid composition without the modification.

67. The cannabinoid composition according to any one of claims 62 to 66, wherein the enhanced user experience comprises improved attentiveness, mood, cheerfulness, relaxation, vigor, calmness, alertness or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

68. The cannabinoid composition according to any one of claims 57 to 67, wherein the dominant terpenes are present at relatively lower levels as a percentage of the total terpenes in the modified terpene profile associated with the cannabinoid composition, as comparable with dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification.

69. The cannabinoid composition according to any one of claims 57 to 67, wherein the non-dominant terpenes are present at relatively higher levels as a percent of the total terpenes in the modified terpene profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification.

70. The cannabinoid composition according to claim 68 or 69, wherein the dominant terpenes are present at about 95% or less, about 90% or less, about 85% or less, or about 80% or less relative to the total terpenes of the modified terpene profile associated with the cannabinoid composition.

71. The cannabinoid composition according to claim 68 or 69, wherein the non-dominant terpenes are present at about 5% or greater, preferably about 10% or greater, preferably about 15% or greater, or preferably about 20% or greater relative to the total terpenes of the modified terpene profile associated with the cannabinoid composition.

72. The cannabinoid composition according to claim 58 or 59, wherein the subset of the dominant terpenes and the non-dominant terpenes associated with the cannabinoid composition is different as comparable with a subset of dominant terpenes and non-dominant terpenes associated with the reference cannabinoid composition without the modification.

73. The cannabinoid composition according to claim 72, wherein the subset of the dominant terpenes and non-dominant terpenes comprises at least lor more, at least 2 or more, or at least 3 or more terpenes that are different as comparable to the reference cannabinoid composition without the modification.

74. The cannabinoid composition according to any one of claims 57 to 73 further comprising at least one cannabinoid.

75. The cannabinoid composition according to claim 74, wherein the at least one cannabinoid is present in an amount of from about 0.001 mg/mL to about 10 g/mL.

76. The cannabinoid composition according to claim 74 or 75, wherein the at least one cannabinoid is cannabidiol (CBD), tetrahydrocannabinol (THC) or a mixture thereof.

77. The cannabinoid composition according to any one of claims 74 to 76, wherein the cannabinoid is a mixture of THC and CBD in the (w/w) ratio of between about 1: 1000 to about 1000: 1.

78. The cannabinoid composition according to any one of claims 74 to 77, wherein the cannabinoid is an isolated cannabinoid having > 90%, > 95%, > 98%, > 99% or > 99.5% purity present in at least one carrier oil.

79. A cannabinoid composition comprising a modified terpene profile comprising dominant terpenes and non-dominant terpenes and a modified cannabinoid profile comprising dominant cannabinoids and non-dominant cannabinoids, wherein the terpenes and the cannabinoids are present in amounts effective to generate an enhanced user experience as comparable to a reference cannabinoid composition without the modification.

80. The cannabinoid composition according to claim 79, wherein the dominant terpenes and non dominant terpenes comprise a subset of terpenes having increased influence over the enhanced user experience as comparable to a reference cannabinoid composition without the modification.

81. The cannabinoid composition according to claim 79, wherein the dominant terpenes and non dominant terpenes comprise a subset of at least 5, preferably at least 7, or preferably at least 10 terpenes having increased influence over the enhanced user experience as comparable to a reference cannabinoid composition without the modification.

82. The cannabinoid composition according to claim 80 or 81, wherein the subset of the dominant terpenes and non-dominant terpenes having the increased influence over the enhanced user experience are different as comparable to a subset of the dominant terpenes and non-dominant terpenes that represent the combined highest concentration in the modified terpene profile.

83. The cannabinoid composition according to claim 82, wherein the subset of the dominant terpenes and non-dominant terpenes having the increased influence over the enhanced user experience comprises at least 1, at least 2, or at least 3 additional non-dominant terpenes.

84. The cannabinoid composition according to any one of claims 79 to 83, wherein the enhanced user experience associated with the modified terpene profile comprises improved organoleptic effects, and/or improved physiological effects, preferably extended duration, shortened onset time, reduced background effects of the terpenes or a combination thereof, as comparable to a reference cannabinoid composition without the modification.

85. The cannabinoid composition according to claim 84, wherein the enhanced user experience comprises improved aroma or flavor effects, preferably improved aroma or flavor intensity, longevity, character or a combination thereof, as comparable to the reference cannabinoid without the modification.

86. The cannabinoid composition according to claim 84, wherein the enhanced user experience comprises reduced odor, preferably odorless, as comparable to the reference cannabinoid composition without the modification.

87. The cannabinoid composition according to any one of claims 84 to 86, wherein the enhanced user experience comprises improved attentiveness, mood, cheerfulness, relaxation, vigor, calmness, alertness or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

88. The cannabinoid composition according to any one of claims 79 to 87, wherein the dominant terpenes are present at relatively lower levels as a percent of the total terpenes in the modified terpene profile associated with the cannabinoid composition as comparable with dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification.

89. The cannabinoid composition according to any one of claims 79 to 88, wherein the non-dominant terpenes are present at relatively higher levels as a percent of the total terpenes in the modified terpene profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a terpene profile associated with the reference cannabinoid composition without the modification.

90. The cannabinoid composition according to claim 88 or 89, wherein the dominant terpenes are present at about 95% or less, about 90% or less, about 85% or less, or about 80% or less relative to the total terpenes of the modified terpene profile associated with the cannabinoid composition.

91. The cannabinoid composition according to claim 88 or 89, wherein the non-dominant terpenes are present at about 5% or greater, about 10% or greater, about 15% or greater, or about 20% or greater relative to the total terpenes of the modified terpene profile associated with the cannabinoid composition.

92. The cannabinoid composition according to claim 80 or 81, wherein the subset of the dominant terpenes and the non-dominant terpenes associated with the cannabinoid composition is different as comparable with a subset of dominant terpenes and non-dominant terpenes associated with the reference cannabinoid composition without the modification.

93. The cannabinoid composition according to claim 92, wherein the subset of the dominant terpenes and the non-dominant terpenes comprises at least one or more, at least two or more, or at least three or more terpenes that are different as comparable to a reference cannabinoid composition without the modification.

94. The cannabinoid composition according to claim 80 or 81, wherein the dominant cannabinoids and the non-dominant cannabinoids comprise a subset of cannabinoids having increased influence over the enhanced user experience as comparable with a subset of dominant terpenes and non-dominant terpenes associated with the reference cannabinoid composition without the modification.

95. The cannabinoid composition according to claim 94, wherein the subset of the dominant terpenes and non-dominant terpenes comprises at least 1 or more, at least 2 or more, or at least 3 or more terpenes that are different as comparable to the reference cannabinoid composition without the modification.

96. The cannabinoid composition according to any one of claims 79 to 95, wherein the dominant cannabinoids and non-dominant cannabinoids comprise a subset of cannabinoids having increased influence over the enhanced user experience as comparable to the reference cannabinoid composition without the modification.

97. The cannabinoid composition according to claim 96, wherein the subset of the dominant cannabinoids and non-dominant cannabinoids having increased influence over the enhanced user experience are different as comparable to a subset of the dominant cannabinoids and non-dominant cannabinoids that represent the combined highest concentration in the modified cannabinoid profile.

98. The cannabinoid composition according to claim 97, wherein the difference comprises different levels of the cannabinoids, different types of the cannabinoids or both.

99. The cannabinoid composition according to any one of claims 79 to 98, wherein the subset of the dominant cannabinoids and non-dominant cannabinoids comprises at least 1 or more, at least 2 or more cannabinoids, or at least 3 or more cannabinoids that are different as comparable to the reference cannabinoid composition without the modification.

100. The cannabinoid composition according to any one of claims 79 to 99, wherein the enhanced user experience associated with the modified cannabinoid profile comprises improved psychoactive effects, decreased side effects or symptoms or both as comparable to a reference cannabinoid composition without the modification.

101. The cannabinoid composition according to claim 100, wherein the enhanced user experience comprises improved psychoactive intensity, longevity, character or a combination thereof, as comparable to the reference cannabinoid composition without the modification.

102. The cannabinoid composition according to claim 101, wherein the improved psychoactive effects comprises enhanced euphoria, a sense of relaxation, an energetic feeling or a combination thereof.

103. The cannabinoid composition according to claim 100, wherein the decreased side effects or symptoms are selected from dysphoria, anxiety, panic, impairment of memory, reductions in psychomotor and cognitive performance, disordered perception of the passage of time, schizophrenic psychosis, tiredness, dizziness, tachycardia, orthostatic hypotension, dry mouth, reduced lacrimation, muscle relaxation, increased appetite, potential irreversible cognitive impairments or a combination thereof.

104. The cannabinoid composition according to any one of claims 79 to 103, wherein the dominant cannabinoids are selected from the group consisting of tetrahydrocannabinol (THC), cannabidiol (CBD), cannabinol (CBN), and a combination thereof, preferably natural or synthetic analogues thereof, and/or derivatives thereof.

105. The cannabinoid composition according to any one of claims 79 to 104, wherein the non-dominant cannabinoids are selected from the group consisting of cannabichromene (CBC), cannabinol (CBN), cannabigerol (CBG), cannabielsoin (CBE), cannabicyclol (CBL), cannabicitran (CBT), cannabivarin (CBV), tetrahydrocannabivarin (THCV), cannabidivarin (CBDV), cannabichromevarin (CBCV), cannabigerovarin (CBGV), cannabigerol monomethyl ether (CBGM), A9-Tctrahydrocannabiphorol (A9-THCP), A9-Tctrahydrocannabiitol (A9-THCB), D8- Tetrahydrocannabinol (A8-THC), A6a.1 Oa-Tctrahydrocannabinol (A6a.1 Oa-THC). D8- Tetrahydrocannabivarin (A8-THCV) and a combination thereof, preferably natural or synthetic analogues thereof, and/or derivatives thereof.

106. The cannabinoid composition according to any one of claims 79 to 105, wherein the dominant cannabinoids are present at relatively lower levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with dominant cannabinoids present in a cannabinoid profile associated with the reference cannabinoid composition without the modification.

107. The cannabinoid composition according to any one of claims 79 to 106, wherein the non-dominant cannabinoids are present at relatively higher levels as a percent of the total cannabinoids in the modified cannabinoid profile associated with the cannabinoid composition as comparable with non-dominant terpenes present in a cannabinoid profile associated with the reference cannabinoid composition without the modification.

108. The cannabinoid composition according to claim 94, wherein the subset of the dominant cannabinoids and the non-dominant cannabinoids associated with the cannabinoid composition is different as comparable with a subset of dominant and non-dominant cannabinoids associated with the reference cannabinoid composition without the modification.

109. A method of formulating a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified cannabinoid profile as defined in any one of claims 57 to 78; and b) selecting dominant and non-dominant cannabinoids based on the modified cannabinoid profile.

110. The method according to claim 109, wherein the selection is based on the modified cannabinoid profile’s influence on the enhanced user experience.

111. A method of formulating a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified terpene profile as defined in any one of claims 57 to 78; and b) selecting dominant terpenes and non-dominant terpenes based on the modified terpene profile.

112. The method according to claim 111, wherein the selection is based on the modified terpene profile’s influence on the enhanced user experience.

113. A method of formulating a cannabinoid composition having an enhanced user experience comprising: a) receiving a modified cannabinoid profile and a modified terpene profile as defined in any one of claims 79 to 108; b) selecting dominant cannabinoids and non-dominant cannabinoids based on the modified cannabinoid profile; and c) selecting dominant terpenes and non-dominant terpenes based on the modified terpene profile.

114. The method according to claim 113, wherein the selection is based on the modified cannabinoid profile’s and the modified terpene profile’s influence on the enhanced user experience.

115. A cannabinoid product comprising the cannabinoid composition as defined in any one of claims 39 to 56.

116. The cannabinoid product according to claim 115 further comprising flavorants, aromatics or both.

117. The cannabinoid product according to claim 115 or 116 selected from a liquid beverage, a human edible product, a pet edible product or an inhalant product.

118. The cannabinoid product according to claim 117, wherein the liquid beverage is selected from the group consisting of carbonated drink, nitrogenated drink, natural fruit juice, synthetic fruit juice, natural vegetable juice, synthetic vegetable juice, distilled water, alkaline water, purified water, mineral water, coconut water, sparkling water, flavored water, coffee, tea, herbal tea, energy drink, non-alcoholic beverage, alcoholic beverage, tincture and cola beverage.

119. The cannabinoid product according to claim 117, wherein the human edible product is selected from the group consisting of gums, hard candies, soft candies, gummy candies, jellies, lozenges, chewing or bubble gums, and mints.

120. The cannabinoid product according to claim 117, wherein the pet edible product is an edible pet food or an edible pet raw.

121. The cannabinoid product according to claim 117, wherein the inhalant product is a vaporizer inhalant, preferably a recreation vaporizer inhalant.

122. A method of enhancing a user experience of a cannabinoid product comprising, providing the cannabinoid product as defined in any one of claims 115 to 121.

123. The method according to claim 122, wherein the enhanced user experience provides improved psychoactive effects, decreased side effects or symptoms or both as comparable to a reference cannabinoid product without the modified cannabinoid profile.

124. The method according to claim 123, wherein the improved psychoactive effects comprise improved psychoactive intensity, longevity, character or a combination thereof.

125. The method according to claim 124, wherein the decreased side effects or symptoms comprise decreased dysphoria, anxiety, panic, impairment of memory, reductions in psychomotor and cognitive performance, disordered perception of the passage of time, schizophrenic psychosis, tiredness, dizziness, tachycardia, orthostatic hypotension, dry mouth, reduced lacrimation, muscle relaxation, increased appetite, potential irreversible cognitive impairments or a combination thereof.

126. The method according to any one of claims 122 to 125, wherein the user experience is enhanced during inhalation of the cannabinoid product.

127. A cannabinoid product comprising the cannabinoid composition as defined in any one of claims57 to 78.

128. The cannabinoid product according to claim 119 further comprising flavorants, aromatics or both.

129. The cannabinoid product according to claim 127 or 128 selected from a liquid beverage, a human edible product, a pet edible product or an inhalant product.

130. The cannabinoid product according to claim 129, wherein the liquid beverage is selected from the group consisting of carbonated drink, nitrogenated drink, natural fruit juice, synthetic fruit juice, natural vegetable juice, synthetic vegetable juice, distilled water, alkaline water, purified water, mineral water, coconut water, sparkling water, flavored water, coffee, tea, herbal tea, energy drink, non-alcoholic beverage, alcoholic beverage, tincture and cola beverage.

131. The cannabinoid product according to claim 129, wherein the human edible product is selected from the group consisting of gums, hard candies, soft candies, gummy candies, jellies, lozenges, chewing or bubble gums, and mints.

132. The cannabinoid product according to claim 129, wherein the edible pet product is an edible pet food or an edible pet raw.

133. The cannabinoid product according to claim 129, wherein the inhalant product is a vaporizer inhalant, preferably a recreation vaporizer inhalant.

134. A method of enhancing a user experience of a cannabinoid product comprising, providing the cannabinoid product as defined in any one of claims 127 to 133.

135. The method according to claim 134, wherein the enhanced user experience provides improved organoleptic effects, improved physiological effects or both as comparable to a reference cannabinoid product without the modified terpene profile.

136. The method according to claim 135, wherein the improved organoleptic effects are selected from the group consisting of improved aroma, improved flavor, reduced odor, and a combination thereof.

137. The method according to claim 135, wherein the improved physiological effects are selected from the group consisting of attentiveness, mood (e.g., cheerfulness), relaxation, vigor, calmness, alertness, and a combination thereof.

138. The method according to any one of claims 134 to 137, wherein the user experience is enhanced during inhalation of the cannabinoid product.

139. A cannabinoid product comprising the cannabinoid composition as defined in any one of claims 79 to 108.

140. The cannabinoid product according to claim 139 further comprising flavorants, aromatics or both.

141. The cannabinoid product according to claim 139 or 140 selected from a liquid beverage, a human edible product, a pet edible product or an inhalant product.

142. The cannabinoid product according to claim 141, wherein the liquid beverage is selected from the group consisting of carbonated drink, nitrogenated drink, natural fruit juice, synthetic fruit juice, natural vegetable juice, synthetic vegetable juice, distilled water, alkaline water, purified water, mineral water, coconut water, sparkling water, flavored water, coffee, tea, herbal tea, energy drink, non-alcoholic beverage, alcoholic beverage, tincture and cola beverage.

143. The cannabinoid product according to claim 141, wherein the human edible product is selected from the group consisting of gums, hard candies, soft candies, gummy candies, jellies, lozenges, chewing or bubble gums, and mints.

144. The cannabinoid product according to claim 141, wherein the pet edible product is an edible pet food or an edible pet raw.

145. The cannabinoid product according to claim 141, wherein the inhalant product is a vaporizer inhalant, preferably a recreation vaporizer inhalant.

146. A method of enhancing a user experience of a cannabinoid product comprising, providing the cannabinoid product as defined in any one of claims 139 to 145.

147. The method according to claim 146, wherein the enhanced user experience is selected from improved psychoactive effects, decreased side effects or symptoms, improved organoleptic effects, improved physiological effects or a combination thereof.

148. The method according to claim 147, wherein the improved psychoactive effects comprises improved psychoactive intensity, longevity, character or a combination thereof.

149. The method according to claim 146, wherein the decreased side effects or symptoms comprise decreased dysphoria, anxiety, panic, impairment of memory, reductions in psychomotor and cognitive performance, disordered perception of the passage of time, schizophrenic psychosis, tiredness, dizziness, tachycardia, orthostatic hypotension, dry mouth, reduced lacrimation, muscle relaxation, increased appetite, potential irreversible cognitive impairments or a combination thereof.

150. The method according to claim 146, wherein the improved organoleptic effects comprise improved aroma or flavor effects or reduced odor, preferably improved aroma or flavor intensity, longevity, character, odorless or a combination thereof.

151. The method according to claim 146, wherein the improved physiological effects comprise attentiveness, mood (e.g., cheerfulness), relaxation, vigor, calmness, alertness, or a combination thereof.